Tivity Health (TVTY) 10-K 13 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 06, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Healthways, Inc.
Entity Central Index Key	704415
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,676,272
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Entity Public Float			$515.60

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$1,765	$2,584
Accounts receivable, net	126,559	89,484
Prepaid expenses	10,680	9,228
Other current assets	7,662	6,857
Income taxes receivable	2,917	1,402
Deferred tax asset	13,118	9,667
Total current assets	162,701	119,222
Property and equipment:
Leasehold improvements	39,285	37,463
Computer equipment and related software	316,808	290,392
Furniture and office equipment	23,257	22,881
Capital projects in process	38,389	25,228
Property and equipment, gross	417,739	375,964
Less accumulated depreciation	-252,043	-217,766
Property and equipment, net	165,696	158,198
Other assets	75,550	53,629
Intangible assets, net	69,161	79,162
Goodwill, net	338,800	338,800
Total assets	811,908	749,011
Current liabilities:
Accounts payable	37,204	33,125
Accrued salaries and benefits	24,198	20,157
Accrued liabilities	62,674	32,065
Deferred revenue	8,282	4,496
Contract billings in excess of earned revenue	15,232	17,411
Current portion of long-term debt	20,613	14,340
Current portion of long-term liabilities	2,127	2,822
Total current liabilities	170,330	124,416
Long-term debt	231,112	237,582
Long-term deferred tax liability	32,883	33,320
Other long-term liabilities	72,993	51,003
Stockholders' equity:
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding	0	0
Common stock $.001 par value, 120,000,000 shares authorized, 35,511,221 and 35,107,303 shares outstanding	35	35
Additional paid-in capital	292,346	283,244
Retained earnings	42,439	48,000
Treasury stock, at cost, 2,254,953 shares in treasury	-28,182	-28,182
Accumulated other comprehensive loss	-2,048	-407
Total stockholders' equity	304,590	302,690
Total liabilities and stockholders' equity	$811,908	$749,011

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares outstanding (in shares)	35,511,221	35,107,303
Treasury stock (in shares)	2,254,953	2,254,953

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenues	$742,183		$663,285		$677,170
Cost of services (exclusive of depreciation and amortization of $37,741, $36,183, and $36,094, respectively, included below)	598,280		547,387		533,880
Selling, general and administrative expenses	65,377		61,205		60,888
Depreciation and amortization	53,378		52,791		51,734
Legal settlement charges	17,715		0		0
Restructuring and related charges	0		0		1,773
Operating income	7,433		1,902		28,895
Interest expense	17,581		16,079		14,149
Income (loss) before income taxes	-10,148		-14,177		14,746
Income tax expense (benefit)	-4,587		-5,636		6,722
Net income (loss)	-5,561		-8,541		8,024
Earnings (loss) per share:
Basic (in dollars per share)	($0.16)		($0.25)		$0.24
Diluted (in dollars per share)	($0.16)	[1]	($0.25)	[1]	$0.24
Comprehensive Income (Loss)	($7,202)		($8,019)		$8,884
Weighted average common shares and equivalents
Basic (in shares)	35,302		34,489		33,597
Diluted (in shares)	35,302	[1]	34,489	[1]	33,836
[1]	The assumed exercise of stock-based compensation awards for the years ended December 31, 2014 and December 31, 2013 was not considered because the impact would be anti-dilutive.

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Cost of services, depreciation and amortization	$37,741	$36,183	$36,094

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income (loss)	($5,561)	($8,541)	$8,024
Other comprehensive income (loss)
Net change in fair value of interest rate swaps, net of income taxes of $44, $972, and $493, respectively	171	1,277	780
Foreign currency translation adjustment	-1,812	-755	80
Total other comprehensive income, net of tax	-1,641	522	860
Total comprehensive income (loss), net of tax	($7,202)	($8,019)	$8,884

CONSOLIDATED_STATEMENTS_OF_COM1

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net change in fair value of interest rate swaps, income taxes	$44	$972	$493

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
In Thousands, unless otherwise specified
Balance at Dec. 31, 2011	$0	$33	$247,137	$48,517	($28,182)	($1,789)	$265,716
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)	0	0	0	8,024	0	860	8,884
Exercise of stock options	0	1	2,834	0	0	0	2,835
Tax effect of stock options and restricted stock units	0	0	-5,043	0	0	0	-5,043
Share-based employee compensation expense	0	0	6,371	0	0	0	6,371
Issuance of stock in conjunction with acquisition	0	0	58	0	0	0	58
Balance at Dec. 31, 2012	0	34	251,357	56,541	-28,182	-929	278,821
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)	0	0	0	-8,541	0	522	-8,019
Exercise of stock options	0	1	12,747	0	0	0	12,748
Tax effect of stock options and restricted stock units	0	0	-3,225	0	0	0	-3,225
Share-based employee compensation expense	0	0	7,116	0	0	0	7,116
Issuance of Warrants	0	0	15,150	0	0	0	15,150
Issuance of stock in conjunction with acquisition	0	0	467	0	0	0	467
Other	0	0	-368	0	0	0	-368
Balance at Dec. 31, 2013	0	35	283,244	48,000	-28,182	-407	302,690
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income (loss)	0	0	0	-5,561	0	-1,641	-7,202
Exercise of stock options	0	0	2,851	0	0	0	2,851
Tax effect of stock options and restricted stock units	0	0	-3,737	0	0	0	-3,737
Share-based employee compensation expense	0	0	8,349	0	0	0	8,349
Issuance of Warrants	0	0	1,639	0	0	0	1,639
Balance at Dec. 31, 2014	$0	$35	$292,346	$42,439	($28,182)	($2,048)	$304,590

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income (loss)	($5,561)	($8,541)	$8,024
Adjustments to reconcile net income to net cash provided by operating activities, net of business acquisitions:
Depreciation and amortization	53,378	52,791	51,734
Amortization of deferred loan costs	1,855	1,685	2,284
Amortization of debt discount	6,757	3,140	0
Share-based employee compensation expense	8,349	7,116	6,371
Deferred income taxes	-6,972	-5,077	-1,334
Excess tax benefits from share-based payment arrangements	-525	-718	-492
(Increase) decrease in accounts receivable, net	-38,130	19,099	-23,439
Decrease (increase) in other current assets	1,589	-598	2,984
(Decrease) increase in accounts payable	-9,343	9,224	-995
Increase (decrease) in accrued salaries and benefits	3,165	-5,780	-12,980
Increase (decrease) in other current liabilities	26,990	-1,196	13,637
Other	10,546	383	-5,096
Net cash flows provided by operating activities	52,098	71,528	40,698
Cash flows from investing activities:
Acquisition of property and equipment	-42,991	-41,346	-48,912
Investment in joint ventures	-7,050	-6,507	0
Business acquisitions, net of cash	0	-830	-4,693
Other	-1,164	-1,210	-6,872
Net cash flows used in investing activities	-51,205	-49,893	-60,477
Cash flows from financing activities:
Proceeds from issuance of long-term debt	467,126	352,850	755,550
Payments of long-term debt	-481,515	-529,874	-736,355
Excess tax benefits from share-based payment arrangements	525	718	492
Exercise of stock options	2,851	12,748	2,835
Deferred loan costs	-391	-5,264	-2,547
Proceeds from cash convertible senior notes	0	150,000	0
Proceeds from convertible note	0	20,000	0
Proceeds from sale of warrants	0	15,150	0
Payments for cash convertible note hedge transactions	0	-36,750	0
Change in outstanding checks and other	11,227	526	582
Net cash flows (used in) provided by financing activities	-177	-19,896	20,557
Effect of exchange rate changes on cash	-1,535	-914	117
Net (decrease) increase in cash and cash equivalents	-819	825	895
Cash and cash equivalents, beginning of period	2,584	1,759	864
Cash and cash equivalents, end of period	1,765	2,584	1,759
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	9,503	10,080	12,001
Cash paid during the period for income taxes	2,399	650	2,282
Noncash Activities:
Assets acquired through capital lease obligation	6,702	0	0
Issuance of unregistered common stock associated with Ascentia acquisition	0	0	58
Issuance of unregistered common stock associated with Ornish partnership	$0	$467	$0

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1	Summary of Significant Accounting Policies
	Founded and incorporated in Delaware in 1981, Healthways, Inc. and its wholly-owned subsidiaries provide comprehensive total population health management solutions that are uniquely designed to help people improve their well-being, thereby improving their health and productivity and reducing their health-related costs. Total population health management involves a proactive approach to reducing avoidable disease incidence – a considerable improvement from the more traditional and more costly method of waiting for people to get a disease before acting.
	As used throughout these notes to the consolidated financial statements, unless the context otherwise indicates, the terms "we," "us," "our," or the "Company" refer collectively to Healthways, Inc. and its wholly-owned subsidiaries.
	a.  Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly owned by the Company.  We have eliminated all intercompany profits, transactions and balances.
	b.  Cash and Cash Equivalents - Cash and cash equivalents primarily include cash, tax-exempt debt instruments, commercial paper, and other short-term investments with original maturities of less than three months.
	c.  Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts.  Billed receivables represent fees that are contractually due for services performed, net of contractual allowances (reflected as a reduction of revenue) and allowances for doubtful accounts (reflected as selling, general and administrative expenses). These combined allowances totaled $2.6 million and $2.0 million at December 31, 2014 and December 31, 2013, respectively. Unbilled receivables primarily represent fees recognized for monthly member utilization of fitness facilities under our SilverSneakers® fitness solution,  billed one month in arrears, and certain performance-based fees that  cannot be billed until after they are reconciled with the customer.  Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts and for contractual allowances (such as data reconciliation differences) on a specific identification basis.
	d.  Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives.  We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and other office equipment.  Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years.  Depreciation expense for the years ended December 31, 2014, 2013, and 2012 was $42.2 million, $40.1 million, and $39.1 million, respectively, including amortization of assets recorded under capital leases.
	Net computer software at December 31, 2014 and 2013 was $98.0 million and $99.1 million, respectively.  Amortization expense related to computer software for the years ended December 31, 2014, 2013, and 2012 was $29.9 million, $26.5 million, and $24.9 million, respectively.
	e.  Other Assets - Other assets consist primarily of cash convertible notes hedges, long-term investments, long-term customer incentives, and deferred loan costs net of accumulated amortization.
	f.  Intangible Assets - Intangible assets subject to amortization include customer contracts, acquired technology, patents, distributor and provider networks, a perpetual license, and other intangible assets which we amortize on a straight-line basis over estimated useful lives ranging from three to 25 years.  We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable.
	Intangible assets not subject to amortization at December 31, 2014 and 2013 consist of a trade name of $29.0 million.  We review intangible assets not subject to amortization on an annual basis or more frequently whenever events or circumstances indicate that the assets might be impaired.  See Note 4 for further information on intangible assets.
	g.  Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire.
	We review goodwill for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable.  We allocate goodwill to reporting units based on the reporting unit expected to benefit from the combination.
	We estimate the fair value of our reporting units using a combination of a discounted cash flow model and a market-based approach, and we reconcile the aggregate fair value of our reporting units to our consolidated market capitalization.
	h. Contract Billings in Excess of Earned Revenue - Contract billings in excess of earned revenue primarily represent performance-based fees subject to refund that we have not recognized as revenues because either (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that we are not currently meeting performance targets.
	i. Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank.
	j. Income Taxes - We file a consolidated federal income tax return that includes all of our domestic wholly-owned subsidiaries.  Generally accepted accounting principles in the United States ("U.S. GAAP") generally require that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities.  We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.
	k. Revenue Recognition - We recognize revenue as services are performed when persuasive evidence of an arrangement exists, collectability is reasonably assured, and amounts are fixed or determinable.
	Our fees are generally billed on a PMPM basis or upon member participation, such as the Healthways® SilverSneakers® fitness solution.  For PMPM fees, we generally determine our contract fees by multiplying the contractually negotiated PMPM rate by the number of members covered by our services during the month.  We typically set PMPM rates during contract negotiations with customers based on the value we expect our programs to create and a sharing of that value between the customer and the Company.  Some of our contracts place a portion of our fees at risk based on achieving certain performance metrics, cost savings, and/or clinical outcomes improvements ("performance-based").  Approximately 6% of revenues recorded during the year ended December 31, 2014 were performance-based of which 2% were subject to final reconciliation as of December 31, 2014.
	We generally bill our customers each month for the entire amount of the fees contractually due for the prior month's enrollment, which typically includes the amount, if any, that is performance-based and may be subject to refund should we not meet performance targets.  Fees for participation are typically billed in the month after the services are provided.  Deferred revenues arise from contracts that permit upfront billing and collection of fees covering the entire contractual service period, generally 12 months.  A limited number of our contracts provide for certain performance-based fees that cannot be billed until after they are reconciled with the customer.
	We recognize revenue as follows: (1) we recognize the fixed portion of PMPM fees and fees for service as revenue during the period we perform our services; and (2) we recognize performance-based revenue based on the most recent assessment of our performance, which represents the amount that the customer would legally be obligated to pay if the contract were terminated as of the latest balance sheet date.
	We generally assess our level of performance for our contracts based on medical claims and other data that the customer is contractually required to supply, interim assessments of achievement against performance targets, or metrics available from our operating platforms.  A minimum of four to nine months' data is typically required for us to measure performance.  In assessing our performance, we may include estimates such as medical claims incurred but not reported.  In addition, we may also provide reserves for contractual allowances (such as data reconciliation differences) as appropriate.
	If data is insufficient or incomplete to measure performance, or interim performance measures indicate that we are not meeting performance targets, we do not recognize performance-based fees subject to refund as revenues but instead record them in a current liability account entitled "contract billings in excess of earned revenue."  Only in the event we do not meet performance levels by the end of the measurement period, typically one year, are we contractually obligated to refund some or all of the performance-based fees.  We would only reverse revenues that we had already recognized if performance to date in the measurement period, previously above targeted levels, subsequently dropped below targeted levels.
	During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, we settle any performance-based fees and reconcile healthcare claims and clinical data.  As of December 31, 2014, cumulative performance-based revenues that have not yet been settled with our customers but that have been recognized in the current and prior years totaled approximately $26.0 million, all of which were based on actual data.  Data reconciliation differences, for which we provide contractual allowances until we reach agreement with respect to identified issues, can arise between the customer and us due to customer data deficiencies, omissions, and/or data discrepancies.
	Performance-related adjustments (including any amounts recorded as revenue that were ultimately refunded), changes in estimates, or data reconciliation differences may cause us to recognize or reverse revenue in a current fiscal year that pertains to services provided during a prior fiscal year.  During 2014, 2013 and 2012, we recognized a net increase in revenue of $7.9 million, $8.2 million, and $9.2 million that related to services provided prior to each respective year.
	l.  Earnings (Loss) Per Share – We calculate basic earnings (loss) per share using weighted average common shares outstanding during the period.  We calculate diluted earnings (loss) per share using weighted average common shares outstanding during the period plus the effect of all dilutive potential common shares outstanding during the period unless the impact would be anti-dilutive.  See Note 13 for a reconciliation of basic and diluted earnings (loss) per share.
	m.  Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant.  See Note 12 for further information on share-based compensation.
	n. Derivative Instruments and Hedging Activities – We use derivative instruments to manage risks related to interest expense, foreign currencies, and the cash convertible senior notes (as discussed in Note 6). We account for derivatives in accordance with Financial Accounting Standards Board ("FASB")  Accounting Standards Codification ("ASC") Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative's fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. As permitted under our master netting arrangements, the fair value amounts of our interest rate swaps and foreign currency options and/or forward contracts are presented on a net basis by counterparty in the consolidated balance sheets. See Note 7 for further information on derivative instruments and hedging activities.
	o. Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Recent_Accounting_Standards

Recent Accounting Standards	12 Months Ended
	Dec. 31, 2014
Recent Accounting Standards [Abstract]
Recent Accounting Standards	2	Recent Accounting Standards
	In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-11, "Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists," which requires an entity to present in the financial statements an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset resulting from a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. However, when the above situation is not available at the reporting date or the tax law of the applicable jurisdiction does not require the entity to use the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. ASU No. 2013-11 is effective prospectively for reporting periods beginning after December 15, 2013.  We adopted this standard for the interim period beginning January 1, 2014.  The adoption of this standard did not have a material impact on our consolidated results of operations, financial position, cash flows, or notes to the consolidated financial statements.
	In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-9 which creates FASB Accounting Standards Codification ("ASC") Topic 606, "Revenue from Contracts with Customers" ("ASC 606") and supersedes ASC Topic 605, "Revenue Recognition." The provisions of ASC Topic 606 provide for a single comprehensive principles-based standard for the recognition of revenue across all industries and expanded disclosure about the nature, amount, timing and uncertainty of revenue, as well as certain additional quantitative and qualitative disclosures. The standard is effective for annual periods beginning after December 15, 2016, including interim periods within those years. We are currently evaluating the impact of adopting ASC Topic 606.

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2014
Goodwill [Abstract]
Goodwill	3	Goodwill
	The change in carrying amount of goodwill during the years ended December 31, 2012, 2013, and 2014 is shown below:
	(In thousands)
	Balance, December 31, 2011		$	335,392
	Ascentia purchase			3,303
	Balance, December 31, 2012			338,695
	Other adjustments			105
	Balance, December 31, 2013			338,800
	Other adjustments			—
	Balance, December 31, 2014		$	338,800
	In April 2012, we acquired Ascentia Health Care Solutions ("Ascentia"), a firm that supports and promotes total population health management, patient centered programs, payer strategies and physician practice enhancement programs, for $5.5 million in cash.  In addition, we issued 14,409 unregistered shares of our common stock in connection with the Ascentia acquisition which were valued in the aggregate at $0.1 million.
	As of December 31, 2014 and December 31, 2013, the gross amount of goodwill totaled $521.1 million, and we had accumulated impairment losses of $182.4 million.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2014
Intangible Assets [Abstract]
Intangible Assets	4	Intangible Assets
	Intangible assets subject to amortization at December 31, 2014 consisted of the following:
	(In thousands)		Gross Carrying		Accumulated		Net
			Amount		Amortization
	Customer contracts		$	16,170	$	13,445	$	2,725
	Acquired technology			19,268		16,709		2,559
	Patents			24,711		17,486		7,225
	Distributor and provider networks			8,709		7,711		998
	Perpetual license to survey-based data			31,000		5,315		25,685
	Other			2,140		1,220		920
	Total		$	101,998	$	61,886	$	40,112
	Intangible assets subject to amortization at December 31, 2013 consisted of the following:
	(In thousands)		Gross Carrying		Accumulated		Net
			Amount		Amortization
	Customer contracts		$	59,574	$	51,512	$	8,062
	Acquired technology			29,431		25,589		3,842
	Patents			24,547		15,081		9,466
	Distributor and provider networks			8,709		7,190		1,519
	Perpetual license to survey-based data			30,000		3,986		26,014
	Other			5,077		3,867		1,210
	Total		$	157,338	$	107,225	$	50,113
	Intangible assets subject to amortization are being amortized over estimated useful lives ranging from three to 25 years.  Total amortization expense for the years ended December 31, 2014, 2013, and 2012, was $11.2 million, $12.7 million, and $12.6 million, respectively.  The following table summarizes the estimated amortization expense for each of the next five years and thereafter:
	(In thousands)
	Year ending December 31,
	2015		$	6,778
	2016			4,998
	2017			3,338
	2018			2,714
	2019			2,395
	2020 and thereafter			19,889
	Total		$	40,112
	Intangible assets not subject to amortization at December 31, 2014 and 2013 consist of a trade name of $29.0 million.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Income Taxes	5.                  Income Taxes
	Income tax expense is comprised of the following:
	(In thousands)	Year Ended December 31,
		2014			2013			2012
	Current taxes
	Federal	$	483		$	(1,311	)	$	(1,271	)
	State		269			741			774
	Foreign		1,316			1,693			1,754
	Deferred taxes
	Federal		(4,844	)		(5,842	)		4,803
	State		(1,938	)		(1,018	)		413
	Foreign		127			101			249
	Total	$	(4,587	)	$	(5,636	)	$	6,722
	Our foreign income before income taxes was $5.2 million, $4.5 million, and $4.8 million for the years ended December 31, 2014, 2013, and 2012, respectively.
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  The following table sets forth the significant components of our net deferred tax liability as of December 31, 2014 and 2013:
	(In thousands)	31-Dec-14			31-Dec-13
	Deferred tax asset:
	Accruals and reserves	$	17,769		$	14,159
	Deferred compensation		4,372			3,933
	Share-based payments		9,368			10,703
	Net operating loss carryforwards		7,167			8,303
	Cash conversion derivative and cash convertible notes hedge, respectively		4,459			3,553
	Other assets		3,124			1,486
			46,259			42,137
	Valuation allowance		(3,836	)		(3,630	)
		$	42,423		$	38,507
	Deferred tax liability:
	Property and equipment	$	(44,832	)	$	(44,740	)
	Intangible assets		(11,778	)		(13,418	)
	Cash convertible notes hedge and cash conversion derivative, respectively		(4,459	)		(3,553	)
	Other liabilities		(1,119	)		(449	)
			(62,188	)		(62,160	)
	Net deferred tax liability	$	(19,765	)	$	(23,653	)
	Net current deferred tax asset	$	13,118		$	9,667
	Net long-term deferred tax liability		(32,883	)		(33,320	)
		$	(19,765	)	$	(23,653	)
	Based on the Company's historical and expected future taxable earnings, we believe it is more likely than not that the Company will realize the benefit of the existing deferred tax assets, net of the valuation allowance, at December 31, 2014.
	For 2014, 2013 and 2012, the tax benefit of share-based compensation, excluding the tax benefit related to the deferred tax asset for share-based payments, was recorded as additional paid-in capital.
	We recorded a tax effect of $44,000, $1.0 million, and $0.5 million in 2014, 2013, and 2012, respectively, related to our interest rate swap agreements (see Note 7) to stockholders' equity as a component of accumulated other comprehensive income (loss).
	At December 31, 2014, we had international net operating loss carryforwards totaling approximately $14.5 million with an indefinite carryforward period, approximately $7.3 million of federal loss carryforwards, and approximately $17.2 million of state loss carryforwards.  We have provided a valuation allowance on certain deferred tax assets associated with our international net operating loss carryforwards.  The federal loss carryforwards originating from acquired entities are subject to an annual limitation under Internal Revenue Code Section 382, and expire in 2021 if not utilized.  The state loss carryforwards are expected to be fully utilized during future periods and expire from 2017 through 2032.
	Undistributed earnings of the Company's foreign subsidiaries amounted to approximately $14.9 million as of December 31, 2014. Those earnings are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been recorded thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to both U.S. income taxes (subject to an adjustment for foreign tax credits) and potential withholding taxes payable to the various foreign countries. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits would be available to reduce a portion of the U.S. tax liability.
	The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows:
	(In thousands)	Year Ended December 31,
		2014			2013			2012
	Statutory federal income tax	$	(3,552	)	$	(4,962	)	$	5,161
	State income taxes, less federal income tax benefit		(456	)		(669	)		453
	Permanent items		137			634			389
	Change in valuation allowance		206			388			285
	Prior year tax adjustments		(42	)		140			263
	Uncertain tax position reversal		—			(1,137	)		—
	State income tax credits		(650	)		—			—
	Net impact of foreign earnings		(218	)		(175	)		39
	Other		(12	)		145			132
	Income tax expense (benefit)	$	(4,587	)	$	(5,636	)	$	6,722
	Uncertain Tax Positions
	During 2013, we recorded a $1.1 million reduction to an unrecognized tax benefit due to the expiration of the applicable statutes of limitations for the 2009 tax year. As of December 31, 2014 and 2013, we had $0.3 million of unrecognized tax benefits that, if recognized, would affect our effective tax rate. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.  During 2012, we included an immaterial amount of net interest related to uncertain tax positions as a component of income tax expense. During 2013 and 2014, there were no interest and penalties related to unrecognized tax benefits recorded as income tax expense.
	The aggregate changes in the balance of unrecognized tax benefits, exclusive of interest, were as follows:
	(In thousands)
	Unrecognized tax benefits at December 31, 2012	$	1,348
	Decreases based upon a lapse of the applicable statute of limitations		(1,060	)
	Unrecognized tax benefits at December 31, 2013	$	288
	Decreases based upon tax positions related to prior years		(35	)
	Unrecognized tax benefits at December 31, 2014	$	253
	We file income tax returns in the U.S. Federal jurisdiction and in various state and foreign jurisdictions.  Tax years remaining subject to examination in these jurisdictions include 2011 to present.

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2014
Long-Term Debt [Abstract]
Long-Term Debt	6	Long-Term Debt
	The Company's long-term debt consists of the following at December 31, 2014 and 2013:
	(In thousands)		31-Dec-14			31-Dec-13
	Cash Convertible Notes, net of unamortized discount		$	123,148		$	116,392
	CareFirst Convertible Note			20,000			20,000
	Fifth Amended Credit Agreement:
	Term Loan			97,500			110,000
	Revolver			4,950			3,625
	Capital lease obligations and other			6,127			1,905
				251,725			251,922
	Less: current portion			(20,613	)		(14,340	)
			$	231,112		$	237,582
	1.50% Cash Convertible Senior Notes Due 2018
	On July 16, 2013, we completed the issuance of $150.0 million aggregate principal amount of the cash convertible senior notes due 2018 (the "Cash Convertible Notes"), which bear interest at a rate of 1.50% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2014. The Cash Convertible Notes will mature on July 1, 2018, unless earlier repurchased or converted into cash in accordance with their terms prior to such date. At the option of the holders, the Cash Convertible Notes are convertible into cash based on the conversion rate set forth below only upon occurrence of certain triggering events as defined in the Indenture dated as of July 8, 2013 by and between the Company and U.S. Bank National Association, none of which had occurred as of December 31, 2014. Accordingly, we have classified the Cash Convertible Notes as long-term debt at December 31, 2014 and December 31, 2013. The Cash Convertible Notes are not convertible into our common stock or any other securities under any circumstances. The initial cash conversion rate is approximately 51.38 shares of our common stock per $1,000 principal amount of Cash Convertible Notes (equivalent to an initial conversion price of approximately $19.46 per share of common stock). The Cash Convertible Notes are our senior unsecured obligations and rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the Cash Convertible Notes. As a result of this transaction, we recognized deferred loan costs of approximately $3.9 million, which are being amortized over the term of the Cash Convertible Notes using the effective interest method.
	The cash conversion feature of the Cash Convertible Notes (the "Cash Conversion Derivative") requires bifurcation from the Cash Convertible Notes in accordance with ASC Topic 815, Derivatives and Hedging, and is recorded in other long-term liabilities as a derivative liability and carried at fair value. The fair value of the Cash Conversion Derivative at the time of issuance of the Cash Convertible Notes was $36.8 million, which was recorded as a debt discount for purposes of accounting for the debt component of the Cash Convertible Notes. The debt discount is being amortized over the term of the Cash Convertible Notes using the effective interest method. For the year ended December 31, 2014, we recorded $6.8 million of interest expense related to the amortization of the debt discount based upon an effective interest rate of 5.7%. The net carrying amount of the Cash Convertible Notes at December 31, 2014 and December 31, 2013 was $123.1 million and $116.4 million, respectively, net of the unamortized discount of $26.9 million and $33.6 million, respectively.
	In connection with the issuance of the Cash Convertible Notes, we entered into privately negotiated convertible note hedge transactions (the "Cash Convertible Notes Hedges"), which are cash-settled and are intended to reduce our exposure to potential cash payments that we would be required to make if holders elected to convert the Cash Convertible Notes at a time when our stock price exceeded the conversion price. The initial cost of the Cash Convertible Notes Hedges was $36.8 million. The Cash Convertible Notes Hedges are recorded in other assets as a derivative asset under FASB ASC Topic 815 and are carried at fair value.  See Note 8 for additional information regarding the Cash Convertible Notes Hedges and the Cash Conversion Derivative and their fair values as of December 31, 2014.
	In July 2013, we also sold separate privately negotiated warrants (the "Warrants") initially relating, in the aggregate, to a notional number of shares of our common stock underlying the Cash Convertible Notes Hedges. The Warrants have an initial strike price of approximately $25.95 per share, which effectively increases the conversion price of the Cash Convertible Notes to a 60% premium to our stock price on July 1, 2013. The Warrants will be net share settled by issuing a number of shares of our common stock per Warrant corresponding to the excess of the market price per share of our common stock (as measured on each warrant exercise date under the terms of the Warrants) over the applicable strike price of the Warrants. The Warrants meet the definition of derivatives under the guidance in ASC Topic 815; however, because these instruments have been determined to be indexed to our own stock and meet the criteria for equity classification under ASC Topic 815-40, the Warrants have been accounted for as an adjustment to our additional paid-in-capital.
	If the market value per share of our common stock exceeds the strike price of the warrants, the warrants will have a dilutive effect on net income per share, and the "treasury stock" method will be used in calculating the dilutive effect on earnings per share.
	CareFirst Convertible Note
	On October 1, 2013, we entered into an Investment Agreement (the "Investment Agreement") with CareFirst Holdings, LLC ("CareFirst"), which is in addition to certain existing commercial agreements between us and CareFirst relating to, among other things, disease management and care coordination services (the "Commercial Agreements"). Pursuant to the Investment Agreement, we issued to CareFirst a convertible subordinated promissory note in the aggregate original principal amount of $20 million (the "CareFirst Convertible Note") for a purchase price of $20 million. The CareFirst Convertible Note bears interest at a rate of 4.75% per year, payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each calendar year, beginning on December 31, 2013. The CareFirst Convertible Note may be prepaid only under limited circumstances and upon the terms and conditions specified therein. If the CareFirst Convertible Note has not been fully converted or redeemed in accordance with its terms, it will mature on October 1, 2019.  The CareFirst Convertible Note is subordinate in right of payment to the prior payment in full of (a) all indebtedness of the Company under the Fifth Amended Credit Agreement (as defined below), and (b) any other senior debt of the Company, which currently includes only the Cash Convertible Notes.
	The CareFirst Convertible Note is convertible into shares of our common stock at the conversion rate determined by dividing (a) the sum of the portion of the principal to be converted and accrued and unpaid interest with respect to such principal by (b) the conversion price equal to $22.41 per share of our common stock.  The conversion price is subject to adjustment for stock splits, stock dividends, recapitalizations, reorganizations, reclassifications and similar events.
	CareFirst has an opportunity to earn warrants to purchase shares of our common stock ("CareFirst Warrants") based on achievement of certain quarterly thresholds (the "Revenue Thresholds") for revenue derived from both the Commercial Agreements and from new business to us from third parties as a result of an introduction or referral to us by CareFirst (collectively, the "Quarterly Revenue").  If the Quarterly Revenue is greater than or equal to the applicable Revenue Threshold for any quarter ending on or prior to September 30, 2017, then we will issue to CareFirst a certain number of warrants exercisable for the number of shares of our common stock ("CareFirst Warrant Shares") determined in accordance with the terms of the Investment Agreement unless (i) CareFirst elects to receive a cash payment in accordance with the terms of the Investment Agreement or (ii) there is a change of control. The aggregate number of CareFirst Warrant Shares in any single 12-month period beginning on October 1, 2013 cannot exceed 400,000, and the aggregate number of CareFirst Warrant Shares issuable pursuant to the Investment Agreement cannot exceed 1,600,000. As of December 31, 2014, we had issued CareFirst Warrants totaling 190,683 at a weighted average exercise price of $16.92, all of which were issued in 2014. These CareFirst Warrants may have a dilutive effect on net income per share, and the "treasury stock" method is used in calculating the dilutive effect on earnings per share.
	Also on October 1, 2013, in connection with the execution of the Investment Agreement, we entered into a Registration Rights Agreement with CareFirst, pursuant to which we agreed to use commercially reasonable efforts to cause any registration statement covering an underwritten offering of our common stock for our own account or for the account of any holder of our common stock (other than a registration statement on Form S-4 or Form S-8 or any successor thereto) to include those registrable common shares that any holder of such registrable common shares has requested to be registered.
	The term of the Investment Agreement expires on the earlier of (a) December 31, 2017 and (b) the first date on which no Commercial Agreement is in effect.
	Credit Facility
	On June 8, 2012, we entered into the Fifth Amended and Restated Revolving Credit and Term Loan Agreement (as amended, the "Fifth Amended Credit Agreement").  The Fifth Amended Credit Agreement provides us with a $200.0 million revolving credit facility that expires on June 8, 2017 and includes a swingline sub facility of $20.0 million and a $75.0 million sub facility for letters of credit.  The Fifth Amended Credit Agreement also provides a $200.0 million term loan facility that matures on June 8, 2017, $97.5 million of which remained outstanding at December 31, 2014, and an uncommitted incremental accordion facility of $100.0 million.
	Borrowings under the Fifth Amended Credit Agreement generally bear interest at variable rates based on a margin or spread in excess of either (1) the one-month, two-month, three-month or six-month rate (or with the approval of affected lenders, nine-month or twelve-month rate) for Eurodollar deposits ("LIBOR") or (2) the greatest of (a) the SunTrust Bank prime lending rate, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the "Base Rate"), as selected by the Company.  The LIBOR margin varies between 1.75% and 3.00%, and the Base Rate margin varies between 0.75% and 2.00%, depending on our leverage ratio.  The Fifth Amended Credit Agreement also provides for an annual fee ranging between 0.30% and 0.50% of the unused commitments under the revolving credit facility.  Extensions of credit under the Fifth Amended Credit Agreement are secured by guarantees from all of the Company's active domestic subsidiaries and by security interests in substantially all of the Company's and such subsidiaries' assets.
	On July 1, 2013, we entered into an amendment to the Fifth Amended Credit Agreement, which provided for, among other things, the amendment of certain negative covenants to permit the issuance of and payments related to the Cash Convertible Notes described above as well as increases in the maximum required levels of total funded debt to EBITDA beginning with the quarter ended June 30, 2013. On April 14, 2014 and December 29, 2014, we entered into additional amendments to the Fifth Amended Credit Agreement, which, among other things, (1) amended the calculation of consolidated EBITDA to exclude the Blue Cross Blue Shield of Minnesota ("BCBSMN") legal settlement (discussed in Note 10) and, for any period that includes a fiscal quarter ending on or before December 31, 2015, up to $5 million in the aggregate of accounting charges attributable to the settlement or other satisfaction of litigation liabilities and the incurrence of related expenses, (2) reduced the amount of the accordion facility from $200 million to $100 million, (3) provided that the net cash proceeds of an asset sale or recovery event be deposited with the administrative agent pending reinvestment or application to the payment of loans, and (4) limited the aggregate consideration payable in respect of acquisitions consummated after December 29, 2014 to $150 million. As of December 31, 2014, availability under the revolving credit facility totaled $95.9 million as calculated under the most restrictive covenant.
	We are required to repay outstanding revolving loans under the revolving credit facility in full on June 8, 2017. We are required to repay term loans in quarterly principal installments aggregating (1) 1.250% of the original aggregate principal amount of the term loans during each of the eight quarters beginning with the quarter ended September 30, 2012, (2) 1.875% of the original aggregate principal amount of the term loans during each of the next four quarters beginning with the quarter ending September 30, 2014, and (3) 2.500% of the original aggregate principal amount of the term loans during each of the remaining quarters prior to maturity on June 8, 2017, at which time the entire unpaid principal balance of the term loans is due and payable.
	The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Fifth Amended Credit Agreement, the Cash Convertible Notes, and the CareFirst Convertible Note for each of the next five years and thereafter:
	(In thousands)
	Year ending December 31,
	2015		$	17,500
	2016			20,000
	2017			64,950
	2018			150,000
	2019			20,000
	2020 and thereafter			—
	Total		$	272,450
	The Fifth Amended Credit Agreement contains financial covenants that require us to maintain specified ratios or levels of (1) total funded debt to EBITDA and (2) fixed charge coverage.
	The Fifth Amended Credit Agreement contains various other affirmative and negative covenants that are typical for financings of this type.  Among other things, the Fifth Amended Credit Agreement limits repurchases of the Company's common stock and the amount of dividends that the Company can pay to holders of its common stock.

Derivative_Investments_and_Hed

Derivative Investments and Hedging Activities	12 Months Ended
	Dec. 31, 2014
Derivative Investments and Hedging Activities [Abstract]
Derivative Investments and Hedging Activities	7	Derivative Instruments and Hedging Activities
	We use derivative instruments to manage risks related to interest, foreign currencies, and the Cash Convertible Notes. We account for derivatives in accordance with FASB ASC Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative's fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. As permitted under our master netting arrangements, the fair value amounts of our interest rate swaps and foreign currency options and/or forward contracts are presented on a net basis by counterparty in the consolidated balance sheets.
	Derivative Instruments Designated as Hedging Instruments
	Cash Flow Hedges
	Derivative instruments that are designated and qualify as cash flow hedges are recorded at estimated fair value in the consolidated balance sheets, with the effective portion of the gains and losses being reported in accumulated other comprehensive income or loss ("accumulated OCI").  Cash flow hedges for all periods presented consist solely of interest rate swap agreements, which effectively modify our exposure to interest rate risk by converting a portion of our floating rate debt to fixed rate obligations, thus reducing the impact of interest rate changes on future interest expense. Under these agreements, we receive a variable rate of interest based on LIBOR (as defined in Note 6), and we pay a fixed rate of interest with interest rates ranging from 0.690% to 1.480% plus a spread (see Note 6).  We maintain interest rate swap agreements with current notional amounts of $125.0 million and termination dates ranging from November 2015 to December 2016.  Of this amount, $75.0 million was effective at December 31, 2014, and $50.0 million will become effective in December 2015, as older interest rate swap agreements expire. Gains and losses on these interest rate swap agreements are reclassified to interest expense in the same period during which the hedged transaction affects earnings or the period in which all or a portion of the hedge becomes ineffective. As of December 31, 2014, we expect to reclassify $0.3 million of net losses on interest rate swap agreements from accumulated OCI to interest expense within the next 12 months due to the scheduled payment of interest associated with our debt.
	The following table shows the effect of our cash flow hedges on the consolidated balance sheets during the year ended December 31, 2014 and 2013:
	(In thousands)		For the Year Ended
	Derivatives in Cash Flow Hedging Relationships		31-Dec-14				31-Dec-13
	(Gain) loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect			292				(332	)
	Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect			(507	)			(1,916	)
	Gains and losses representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. During the years ended December 31, 2014 and 2013, there were no gains or losses on cash flow hedges recognized in our consolidated statements of comprehensive income (loss) resulting from hedge ineffectiveness.
	Derivative Instruments Not Designated as Hedging Instruments
	Our Cash Conversion Derivative, Cash Convertible Notes Hedges, and foreign currency options and/or forward contracts do not qualify for hedge accounting treatment under U.S. GAAP and are measured at fair value with gains and losses recognized immediately in the consolidated statements of comprehensive income (loss). These derivative instruments not designated as hedging instruments did not have a material impact on our consolidated statements of comprehensive income (loss) during the years ended December 31, 2014, 2013 and 2012.
	The Cash Conversion Derivative is accounted for as a derivative liability and carried at fair value. In order to offset the risk associated with the Cash Conversion Derivative, we entered into Cash Convertible Notes Hedges which are cash-settled and are intended to reduce our exposure to potential cash payments that we would be required to make if holders elected to convert the Cash Convertible Notes at a time when our stock price exceeded the conversion price. The Cash Convertible Notes Hedges are accounted for as a derivative asset and carried at fair value.
	The gains and losses resulting from changes in the fair values of the Cash Conversion Derivative and the Cash Convertible Notes Hedges are reported in the consolidated statements of comprehensive income (loss) as follows:
		Year Ended
	(In thousands)	31-Dec-14				31-Dec-13				Statements of Comprehensive Income (Loss) Classification
	Cash Convertible Notes Hedges:
	Net unrealized gain (loss)		$	20,259			$	(8,984	)	Selling, general and administrative expense
	Cash Conversion Derivative:
	Net unrealized gain (loss)		$	(20,259	)		$	8,984		Selling, general and administrative expense
	We also enter into foreign currency options and/or forward contracts in order to minimize our earnings exposure to fluctuations in foreign currency exchange rates.  Our foreign currency exchange contracts require current period mark-to-market accounting, with any change in fair value being recorded each period in the consolidated statements of comprehensive income (loss) in selling, general and administrative expenses. At December 31, 2014, we had forward contracts with notional amounts of $24.7 million to exchange foreign currencies, primarily the Australian dollar and Euro, that were entered into in order to hedge forecasted foreign net income (loss) and intercompany debt. We routinely monitor our foreign currency exposures to maximize the overall effectiveness of our foreign currency hedge positions.  We do not execute transactions or hold derivative financial instruments for trading or other purposes.
	The estimated gross fair values of derivative instruments at December 31, 2014 and December 31, 2013, excluding the impact of netting derivative assets and liabilities when a legally enforceable master netting agreement exists, were as follows:
			31-Dec-14										31-Dec-13
	(In thousands)		Foreign currency exchange contracts				Interest rate swap agreements				Cash Convertible Notes Hedges and Cash Conversion Derivative		Foreign currency exchange contracts		Interest rate swap agreements		Cash Convertible Notes Hedges and Cash Conversion Derivative
	Assets:
	Derivatives not designated as hedging instruments:
	Other current assets		$	477			$	—			$	—	$	178	$	—	$	—
	Other assets			—				—				48,025		—		—		27,766
	Total assets		$	477			$	—			$	48,025	$	178	$	—	$	27,766
	Liabilities:
	Derivatives not designated as hedging instruments:
	Accrued liabilities		$	111			$	—			$	—	$	67	$	—	$	—
	Other long-term liabilities			—				—				48,025		—		—		27,766
	Derivatives designated as hedging instruments:
	Other long-term liabilities			—				395				—		—		505		—
	Total liabilities		$	111			$	395			$	48,025	$	67	$	505	$	27,766

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements [Abstract]
Fair Value Measurements	8	Fair Value Measurements
	We account for certain assets and liabilities at fair value.  Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.
	Fair Value Hierarchy
	The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:
	Level 1:  Quoted prices in active markets for identical assets or liabilities;
	Level 2:  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
	Level 3:  Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability.
	Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The following tables present our assets and liabilities measured at fair value on a recurring basis at December 31, 2014 and December 31, 2013:
	(In thousands)		Level 2			Level 3		Gross Fair		Netting (1)			Net Fair
	31-Dec-14							Value					Value
	Assets:
	Foreign currency exchange contracts		$	477		$	—	$	477	$	(111	)	$	366
	Cash Convertible Notes Hedges			—			48,025		48,025		—			48,025
	Liabilities:
	Foreign currency exchange contracts		$	111		$	—	$	111	$	(111	)	$	—
	Interest rate swap agreements			395			—		395		—			395
	Cash Conversion Derivative			—			48,025		48,025		—			48,025
	(In thousands)		Level 2			Level 3		Gross Fair		Netting (1)			Net Fair
	31-Dec-13							Value					Value
	Assets:
	Foreign currency exchange contracts		$	178		$	—	$	178	$	(57	)	$	121
	Cash Convertible Notes Hedges			—			27,766		27,766		—			27,766
	Liabilities:
	Foreign currency exchange contracts		$	67		$	—	$	67	$	(57	)	$	10
	Interest rate swap agreements			505			—		505		—			505
	Cash Conversion Derivative			—			27,766		27,766		—			27,766
	(1) This column reflects the impact of netting derivative assets and liabilities by counterparty when a legally enforceable master netting agreement exists.
	The fair values of forward foreign currency exchange contracts are valued using broker quotations of similar assets or liabilities in active markets.  The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using internal models and third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads. The fair values of the Cash Convertible Notes Hedges and the Cash Conversion Derivative are measured using Level 3 inputs. These instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market data for inputs, such as expected time to maturity of the derivative instruments, the risk-free interest rate, the expected volatility of our common stock and other factors. The Cash Convertible Notes Hedges and the Cash Conversion Derivative were designed such that changes in their fair values would offset one another, with minimal impact to the consolidated statements of comprehensive income (loss). Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is mitigated.
	The following table presents our financial instruments measured at fair value on a recurring basis using unobservable inputs (Level 3):
	(In thousands)		Balance at December 31, 2013			Purchases of Level 3 Instruments		Issuances of Level 3 Instruments		Gains/(Losses) Included in Earnings			Balance at December 31, 2014
	Cash Convertible Notes Hedges		$	27,766		$	—	$	—	$	20,259		$	48,025
	Cash Conversion Derivative			(27,766	)		—		—		(20,259	)		(48,025	)
	The gains and losses included in earnings noted above represent the change in the fair value of these financial instruments and are recorded each period in the consolidated statements of comprehensive income (loss) as selling, general and administrative expenses.
	Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
	We measure certain assets at fair value on a nonrecurring basis in the fourth quarter of our fiscal year, including the following:
	·	reporting units measured at fair value in the first step of a goodwill impairment test; and
	·	indefinite-lived intangible assets measured at fair value for impairment assessment.
	Each of the assets above is classified as Level 3 within the fair value hierarchy.
	During the fourth quarter of 2014, we reviewed goodwill for impairment at the reporting unit level (operating segment or one level below an operating segment). We have two reporting units, domestic and international. The fair value of a reporting unit is the price that would be received to sell the unit as a whole in an orderly transaction between market participants at the measurement date.  We may elect to perform a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value.  However, we elected not to perform a qualitative assessment, instead proceeding to the quantitative review described below.
	We estimated the fair value of our reporting units using a combination of a discounted cash flow model and a market-based approach, and we reconciled the aggregate fair value of our reporting units to our consolidated market capitalization. Estimating fair value requires significant judgments, including management's estimate of future cash flows, which is dependent on internal forecasts, estimation of the long-term growth rate for our business, the useful life over which cash flows will occur, and determination of our weighted average cost of capital, as well as relevant comparable company earnings multiples for the market-based approach. Changes in these estimates and assumptions could materially affect the estimate of fair value and goodwill impairment for each reporting unit.  We determined that the carrying value of goodwill was not impaired based upon the impairment review.
	Also during the fourth quarter of 2014, we estimated the fair value of our indefinite-lived intangible asset, a trade name, using a present value technique, which required management's estimate of future revenues attributable to this trade name, estimation of the long-term growth rate and royalty rate for this revenue, and determination of our weighted average cost of capital.  Changes in these estimates and assumptions could materially affect the estimate of fair value for the trade name.  We determined that the carrying value of the trade name was not impaired based upon the impairment review.
	Fair Value of Other Financial Instruments
	In addition to foreign currency exchange contracts, interest rate swap agreements, the Cash Convertible Notes Hedges, and the Cash Conversion Derivative, the estimated fair values of which are disclosed above, the estimated fair value of each class of financial instruments at December 31, 2014 was as follows:
	Cash and cash equivalents – The carrying amount of $1.8 million approximates fair value because of the short maturity of those instruments (less than three months).
	Long-term debt – The estimated fair value of outstanding borrowings under the Fifth Amended Credit Agreement, which includes a revolving credit facility and a term loan facility, the Cash Convertible Notes and the CareFirst Convertible Note (see Note 6) are determined based on the fair value hierarchy as discussed above.  The revolving credit facility and the term loan facility are not actively traded and therefore are classified as Level 2 valuations based on the market for similar instruments.  The estimated fair value is based on the average of the prices set by the issuing bank given current market conditions and is not necessarily indicative of the amount we could realize in a current market exchange. The estimated fair value and carrying amount of outstanding borrowings under the Fifth Amended Credit Agreement at December 31, 2014 are $101.9 million and $102.5 million, respectively.
	The Cash Convertible Notes are actively traded and therefore are classified as Level 1 valuations. The estimated fair value at December 31, 2014 was $176.4 million, which is based on the last traded price of the Cash Convertible Notes on December 31, 2014, and the par value was $150.0 million. The carrying amount of the Cash Convertible Notes at December 31, 2014 was $123.1 million, which is net of the debt discount discussed in Note 6.
	The CareFirst Convertible Note was issued at its fair value of $20.0 million on October 1, 2013. It is not actively traded and is not based upon either an observable market, other than the market for our stock, or on an observable index and is therefore classified as a Level 3 valuation. At December 31, 2014, the carrying amount of the CareFirst Convertible Note of $20.0 million approximates fair value because there were no factors present that would materially impact the fair value since its issuance on October 1, 2013.

Other_LongTerm_Liabilities

Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2014
Other Long-Term Liabilities [Abstract]
Other Long-Term Liabilities	9	Other Long-Term Liabilities
	Other long-term liabilities consist primarily of the Cash Conversion Derivative (see Notes 6 and 7), deferred rent (see Note 11), a deferred compensation plan, and accrued performance cash (if pre-established performance metrics are met).
	We have a non-qualified deferred compensation plan under which certain employees may defer a portion of their salaries and receive a Company matching contribution plus a discretionary contribution based on the Company's performance against financial targets.  Company contributions vest equally over four years.  We do not fund the plan and carry it as an unsecured obligation.  Participants in the plan elect payout dates for their account balances, which can be no earlier than four years from the beginning of the plan year.
	As of December 31, 2014 and 2013, other long-term liabilities included vested amounts under the non-qualified deferred compensation plan of $7.4 million and $6.8 million, respectively, net of the current portions of $0.5 million and $1.0 million, respectively.  For the next five years ending December 31, 2019 we must make estimated plan payments of $0.5 million, $1.2 million, $0.3 million, $0.3 million, and $0.1 million, respectively.
	In addition, under our stock incentive plan, we issue performance-based cash awards to certain employees based on pre-established performance metrics. Based on achievement of the performance metrics, the awards vest on the fourth anniversary of the grant date and are paid shortly thereafter.
	As of December 31, 2014 and 2013, accrued performance cash totaled $0.9 million and $0, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Commitments and Contingencies	10	Commitments and Contingencies
	Contract Disputes
	On January 25, 2010, BCBSMN issued notice of arbitration with the American Arbitration Association in Minneapolis in accordance with the terms of the contract alleging violations of certain contract provisions and seeking recoupment of an unspecified amount of payments made to us under the contract. We believe we performed our services in compliance with the terms of our agreement and that the assertions made in the arbitration notice are without merit.  On August 3, 2011, we asserted numerous counterclaims against BCBSMN. On April 15, 2014, we entered into an agreement with BCBSMN to resolve this dispute.  Under the terms of the agreement, we agreed to pay BCBSMN in two separate installments: $4 million, which was paid in April 2014, and $5.5 million which was paid in January 2015.
	On September 10, 2012, Plastipak Packaging, Inc. ("Plastipak") filed suit in the Circuit Court for Wayne County, Michigan seeking damages relating to an alleged breach of a services agreement with us. On February 4, 2015, the Court announced an award of $7.2 million in favor of Plastipak, which amount is included in our consolidated balance sheet and results of operations as of and for the year ended December 31, 2014.
	Junk Fax Prevention Act Lawsuits
	On September 16, 2014, Healthways and its wholly owned subsidiary, Healthways WholeHealth Networks, Inc. ("HWHN"), were named in a putative class action lawsuit filed in the Superior Court of California, County of Los Angeles, seeking damages and other relief relating to alleged violations of the Telephone Consumer Protection Act ("TCPA"), as amended by the Junk Fax Prevention Act ("JFPA"), in connection with faxes allegedly transmitted to members of HWHN's network of complementary and alternative care practitioners. The JFPA prohibits sending an "unsolicited advertisement" to a fax machine and requires the sender to provide a notice to allow a recipient to "opt out" of future fax transmissions (including, pursuant to rules promulgated by the Federal Communications Commission ("FCC"), those sent with the prior express invitation or permission of the recipient). The complaint seeks damages in excess of $5 million. The case has been removed to the United States District Court for the Central District of California, Eastern Division ("California Matter").
	On December 22, 2014, HWHN was also named in a putative class action lawsuit filed in the United States District Court for the Northern District of Illinois, Eastern Division ("Illinois Matter"), seeking damages and other relief relating to alleged violations of the TCPA, the Illinois Consumer Fraud and Deceptive Business Practices Act, and Illinois common law in connection with faxes allegedly sent to members of HWHN's network of complementary and alternative care practitioners. The complaint seeks damages in an unstated amount.
	We deny the claims and intend to vigorously defend these actions.
	In connection with these actions, on March 2, 2015, Healthways and HWHN filed with the FCC a Petition for Retroactive Waiver ("Waiver Petition") of the FCC's regulation that requires advertising faxes sent with the prior express invitation or permission of the recipient to include an "opt-out" notice. The FCC has previously granted retroactive waivers of that regulation to several petitioners who were facing lawsuits alleging that the petitioners failed to include the "opt-out" language in fax advertisements sent with the prior express invitation or permission of the recipients. We cannot predict whether the FCC will grant our Waiver Petition or, if granted, the impact on the California Matter or the Illinois Matter.
	Performance Award Lawsuit
	On September 4, 2012, Milton Pfeiffer ("Plaintiff"), claiming to be a stockholder of the Company, filed a putative derivative action against the Company and the Board of Directors (the "Board") in Delaware Chancery Court (the "Court") alleging that the Compensation Committee of the Board and the Board breached their fiduciary duties and violated the Company's 2007 Stock Incentive Plan (the "Plan") by granting Ben R. Leedle, Jr., Chief Executive Officer and President of the Company, discretionary performance awards under the Plan in the form of options to purchase an aggregate of 500,000 shares of the Company's common stock, which consisted of a performance award in November 2011 granting Mr. Leedle the right to purchase 365,000 shares and a performance award in February 2012 granting Mr. Leedle the right to purchase 135,000 shares (the "Performance Awards").  Plaintiff alleges that the Performance Awards exceeded what is authorized by the Plan and that the Company's 2012 proxy statement, in which the Performance Awards are disclosed, is false and misleading.  Plaintiff also alleges that Mr. Leedle breached his fiduciary duties and was unjustly enriched by receiving the Performance Awards.  Plaintiff is seeking, among other things, the rescission or disgorgement of all alleged "excess" awards granted to Mr. Leedle under the Performance Awards, to recover any incidental damages to the Company, and an award of attorneys' fees and expenses.  On November 2, 2012, the Company and the Board filed a Motion to Dismiss because Plaintiff failed to make a demand upon the Board as required by Delaware law.  On November 8, 2013, the Court denied the Company's Motion to Dismiss. On February 21, 2014, the Company filed its answer and intends to vigorously defend the allegations.
	Summary
	We are also subject to other contractual disputes, claims and legal proceedings that arise from time to time in the ordinary course of our business.  While we are unable to estimate a range of potential losses, we do not believe that any of the legal proceedings pending against us as of the date of this report, some of which are expected to be covered by insurance policies, will have a material adverse effect on our financial statements.  As these matters are subject to inherent uncertainties, our view of these matters may change in the future.
	Contractual Commitments
	In January 2008, we entered into a 25-year strategic relationship agreement with Gallup and a global joint venture agreement with Gallup in October 2012 that requires us to make payments over a 5-year period beginning January 2013.  We have minimum remaining contractual cash obligations of $34.5 million related to these agreements.
	In May 2011, we entered into a ten-year applications and technology services outsourcing agreement with HP Enterprise Services, LLC that contains minimum fee requirements.  Total payments over the remaining term, including an estimate for future contractual cost of living adjustments, must equal or exceed a minimum level of approximately $133.3 million; however, based on current required service and equipment level assumptions, we estimate that the remaining payments will be approximately $276.3 million.  The agreement allows us to terminate all or a portion of the services after the first two years provided we pay certain termination fees, which could be material to the Company.

Leases

Leases	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Leases	11	Leases
	We maintain operating lease agreements principally for our corporate office space, our well-being improvement call centers, and our operations support and training offices.  We lease approximately 264,000 square feet of office space in Franklin, Tennessee, which contains our corporate headquarters and one of our well-being improvement call centers.  This lease commenced in March 2008 and expires in February 2023.  We also lease approximately 92,000 square feet of office space in Chandler, Arizona which contains additional corporate colleagues and one of our well-being improvement call centers.  In addition, we lease office space for our six other well-being improvement call center locations for an aggregate of approximately 140,000 square feet of space with lease terms expiring on various dates from 2015 to 2021.  Our operations support and training offices contain approximately 70,000 square feet in aggregate and have lease terms expiring from 2015 to 2022.
	Our corporate office lease agreement contains escalation clauses and provides for two renewal options of five years each at then prevailing market rates.  The base rent for the initial 15-year term ranges from $4.3 million to $6.6 million per year over the term of the lease.  The landlord provided a tenant improvement allowance equal to approximately $10.7 million.  We record leasehold improvement incentives as deferred rent and amortize them as reductions to rent expense over the lease term.
	Most of our operating leases include escalation clauses, some of which are fixed amounts, and some of which reflect changes in price indices.  We recognize rent expense on a straight-line basis over the lease term.  Certain operating leases contain renewal options to extend the lease for additional periods.  For the years ended December 31, 2014, 2013, and 2012, rent expense under lease agreements was approximately $13.2 million, $12.9 million, and $12.9 million, respectively.  Our capital lease obligations, which primarily include computer equipment leases, are included in long-term debt and the current portion of long-term debt.
	The following table summarizes our future minimum lease payments under all capital leases and non-cancelable operating leases for each of the next five years and thereafter:
	(In thousands)		Capital			Operating
	Year ending December 31,		Leases			Leases
	2015		$	1,709		$	13,724
	2016			1,442			13,443
	2017			1,258			13,006
	2018			365			13,282
	2019			—			12,553
	2020 and thereafter			—			23,903
	Total minimum lease payments		$	4,774		$	89,911
	Less: amount representing interest			(238	)
	Present value of minimum lease payments			4,536
	Less: current portion			(1,576	)
			$	2,960

ShareBased_Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2014
Share-Based Compensation [Abstract]
Share-Based Compensation	12.        Share-Based Compensation
	We have several stockholder-approved stock incentive plans for our employees and directors.  We currently have four types of share-based awards outstanding under these plans: stock options, restricted stock units, restricted stock, and performance-based stock units (beginning in June 2014).  A portion of the performance-based stock units granted also includes a market condition based on our total shareholder return.
	We grant options under these plans at market value on the date of grant, except in the case of certain performance awards which may be granted at a price above market value.  The options generally vest over four years based on service conditions and expire ten years from the date of grant.  Restricted stock units and restricted stock awards generally vest over four years. Performance-based stock units have a multi-year performance period and vest four years from the grant date. We recognize share-based compensation expense for options, restricted stock units, and restricted stock awards on a straight-line basis over the vesting period. We recognize compensation expenses for performance-based stock units over the requisite service period if it is probable that the performance target will be achieved, and we subsequently adjust the expense if the probability assessment changes. All awards generally provide for accelerated vesting upon a change in control or normal or early retirement (as defined in the applicable stock incentive plan).  At December 31, 2014, we had reserved approximately 0.5 million shares for future equity grants under our stock incentive plan.
	Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2014, 2013, and 2012.  We did not capitalize any share-based compensation costs during these periods.
		Year Ended
		December 31,			December 31,			December 31,
	(In millions)	2014			2013			2012
	Total share-based compensation	$	8.3		$	7.1			$	6.4
	Share-based compensation included in cost of services		3.8			2.9				3
	Share-based compensation included in selling, general and administrative expenses		4.5			4.2				3.4
	Total income tax benefit recognized		3.3			2.8				2.5
	As of December 31, 2014, there was $21.4 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the stock incentive plans.  That cost is expected to be recognized over a weighted average period of 2.2 years.
	Stock Options
	We use a lattice-based binomial option valuation model ("lattice binomial model") to estimate the fair values of stock options.  We base expected volatility on historical volatility due to the low volume of traded options on our common stock.  The expected term of options granted is derived from the output of the lattice binomial model and represents the period of time that options granted are expected to be outstanding.  We used historical data to estimate expected option exercise and post-vesting employment termination behavior within the lattice binomial model.
	The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates under each of the option valuation models for the years ended December 31, 2014, 2013 and 2012:
		Year Ended December 31,
		2014			2013				2012
	Weighted average grant-date fair value of options per share	$	9.05		$	7.29			$	4.01
	Assumptions:
	Expected volatility		54.6	%		53.8	%			54.4	%
	Expected dividends		—			—				—
	Expected term (in years)		4.7			5.1				5.1
	Risk-free rate		2.4	%		1.9	%			2	%
	A summary of option activity as of December 31, 2014 and the changes during the year then ended is presented below:
	Options	Shares (thousands)			Weighted				Weighted Average			Aggregate Intrinsic Value (thousands)
					Average Exercise				Remaining
					Price				Contractual
					Per Share				Term
	Outstanding at January 1, 2014		4,325		$	15.09
	Granted		98			16.6
	Exercised		(224	)		12.75
	Forfeited		(80	)		12.87
	Expired		(555	)		29.94
	Outstanding at December 31, 2014		3,564		$	13.01				6.4		$	27,511
	Exercisable at December 31, 2014		1,942		$	14.26				5.5		$	13,940
	The total intrinsic value, which represents the difference between the market price of the underlying common stock and the option's exercise price, of options exercised during the years ended December 31, 2014, 2013, and 2012 was $1.1 million, $3.2 million, and $1.3 million, respectively.
	Cash received from option exercises under all share-based payment arrangements during 2014 was $2.9 million.  The actual tax benefit realized during 2014 for the tax deductions from option exercises totaled $0.4 million.  We issue new shares of common stock upon exercise of stock options.
	Nonvested Shares
	The fair value of restricted stock and restricted stock units is determined based on the closing bid price of the Company's common stock on the grant date.  The weighted average grant-date fair value of restricted stock and restricted stock units granted during the years ended December 31, 2014, 2013 and 2012, was $16.72, $13.12, and $8.29, respectively. The fair value of performance-based stock units is determined based on the closing bid price of the Company's common stock on the grant date, except that the Monte Carlo simulation valuation model is used to determine the fair value of any performance-based stock units with a market condition. The weighted average grant-date fair value of all performance-based stock units granted during the year ended December 31, 2014 was $14.77. No performance-based stock units were granted during the years ended December 31, 2013 and 2012.
	The following table sets forth a summary of our nonvested shares as of December 31, 2014 as well as activity during the year then ended.  The total grant-date fair value of shares vested during the years ended December 31, 2014, 2013, and 2012 was $2.5 million, $3.1 million, and $3.6 million, respectively.
		Restricted Stock Units							Performance-Based Stock Units
	Nonvested Shares	Shares (thousands)			Weighted Average Grant Date Fair Value Per Share				Shares (thousands)			Weighted Average Grant Date Fair Value Per Share
	Nonvested at January 1, 2014		841		$	10.44				—		$	—
	Granted		475			16.72				341			14.77
	Vested		(231	)		10.83				—			—
	Forfeited		(38	)		11.8				—			—
	Nonvested at December 31, 2014		1,047		$	13.15				341		$	14.77

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2014
Earnings (Loss) Per Share [Abstract]
Earnings (Loss) Per Share	13	Earnings (Loss) Per Share
	The following is a reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share for the years ended December 31, 2014, 2013, and 2012:
	(In thousands except per share data)		Year Ended December 31,
	Numerator:		2014			2013			2012
	Net income (loss)		$	(5,561	)	$	(8,541	)	$	8,024
	Denominator:
	Shares used for basic earnings (loss) per share			35,302			34,489			33,597
	Effect of dilutive stock options and restricted stock units outstanding:
	Non-qualified stock options (1)			—			—			37
	Restricted stock units (1)			—			—			202
	Shares used for diluted earnings (loss) per share (1)			35,302			34,489			33,836
	Earnings (loss) per share:
	Basic		$	(0.16	)	$	(0.25	)	$	0.24
	Diluted (1)		$	(0.16	)	$	(0.25	)	$	0.24
	Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive:
	Non-qualified stock options			1,865			3,234			4,926
	Restricted stock units			453			334			193
	Performance-based stock units			20			—			—
	Warrants related to Cash Convertible Notes			7,707			7,707			—
	CareFirst Convertible Note			892			892			—
	CareFirst Warrants			87			—			—
	(1) The assumed exercise of stock-based compensation awards for the years ended December 31, 2014 and December 31, 2013 was not considered because the impact would be anti-dilutive.

Accumulated_OCI

Accumulated OCI	12 Months Ended
	Dec. 31, 2014
Accumulated OCI [Abstract]
Accumulated OCI	14.            Accumulated OCI
	The following tables summarize the changes in accumulated OCI, net of tax, for the twelve months ended December 31, 2014 and 2013:
	(In thousands)		Net Change in Fair Value of Interest Rate Swaps				Foreign Currency Translation Adjustments				Total
	Accumulated OCI, net of tax, as of January 1, 2014		$	(513	)		$	106			$	(407	)
	Other comprehensive income (loss) before reclassifications, net of tax			(135	)			(1,812	)			(1,947	)
	Amounts reclassified from accumulated OCI, net of tax			306				—				306
	Net increase (decrease) in other comprehensive income (loss), net of tax			171				(1,812	)			(1,641	)
	Accumulated OCI, net of tax, as of December 31, 2014		$	(342	)		$	(1,706	)		$	(2,048	)
	(In thousands)		Net Change in Fair Value of Interest Rate Swaps				Foreign Currency Translation Adjustments				Total
	Accumulated OCI, net of tax, as of January 1, 2013		$	(1,790	)		$	861			$	(929	)
	Other comprehensive income (loss) before reclassifications, net of tax			189				(755	)			(566	)
	Amounts reclassified from accumulated OCI, net of tax			1,088				—				1,088
	Net increase (decrease) in other comprehensive income (loss), net of tax			1,277				(755	)			522
	Accumulated OCI, net of tax, as of December 31, 2013		$	(513	)		$	106			$	(407	)
	The following table provides details about reclassifications out of accumulated OCI for the years ended December 31, 2014 and 2013:
		Year Ended December 31,								Statement of Comprehensive Income
	(In thousands)	2014				2013				(Loss) Classification
	Interest rate swaps		$	507			$	1,916		Interest expense
				(201	)			(828	)	Income tax benefit
			$	306			$	1,088		Net of tax
	See Note 7 for further discussion of our interest rate swaps.

Stockholder_Rights_Plan

Stockholder Rights Plan	12 Months Ended
	Dec. 31, 2014
Stockholder Rights Plan [Abstract]
Stockholder Rights Plan	15	Stockholder Rights Plan
	On June 19, 2000, our Board adopted a stockholder rights plan under which holders of common stock as of June 30, 2000 received preferred stock purchase rights as a dividend at the rate of one right per share.  As amended in June 2004 and July 2006, each right initially entitled its holder to purchase one one-hundredth of a Series A preferred share at $175.00, subject to adjustment.  Upon becoming exercisable, each right allowed the holder (other than the person or group whose actions have triggered the exercisability of the rights), under alternative circumstances, to buy either securities of the Company or securities of the acquiring company (depending on the form of the transaction) having a value of twice the then current exercise price of the rights. The rights expired on June 15, 2014.

Employee_Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2014
Employee Benefits [Abstract]
Employee Benefits	16	Employee Benefits
	We have a 401(k) Retirement Savings Plan (the "401(k) Plan") available to substantially all of our employees.  Employees can contribute up to a certain percentage of their base compensation as defined in the 401(k) Plan.  The Company matching contributions are subject to vesting requirements.  Company contributions under the 401(k) Plan totaled $3.3 million, $3.1 million, and $2.9 million for the years ended December 31, 2014, 2013, and 2012, respectively.

Segment_Disclosures

Segment Disclosures	12 Months Ended
	Dec. 31, 2014
Segment Disclosures [Abstract]
Segment Disclosures	17	Segment Disclosures
	We have two operating segments (domestic and international) that we have aggregated into one reportable segment, well-being improvement services.  Our integrated well-being improvement services include disease management, health coaching, and wellness and prevention programs. Further, we report revenues from our external customers on a consolidated basis since well-being improvement is the only service that we provide. Long-lived assets and revenue from external customers attributable to our operations in the United States accounted for more than 95% of our consolidated long-lived assets and revenues as of and for the years ended December 31, 2014 and December 31, 2013.
	During 2014 and 2013, we derived approximately 11.6% and 10.5%, respectively, of our revenues from one customer, with no other customer comprising 10% or more of our revenues.

Quarterly_Financial_Informatio

Quarterly Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information (unaudited) [Abstract]
Quarterly Financial Information (unaudited)	18	Quarterly Financial Information (unaudited)
	(In thousands, except per share data)
	Year Ended		First			Second			Third		Fourth
	31-Dec-14
				(1), (2), (4)			(1), (2)		-2		(2), (4)
	Revenues		$	176,777		$	180,613		$	185,656	$	199,136
	Gross margin		$	19,257		$	24,533		$	27,314	$	35,058
	Income (loss) before income taxes		$	(14,884	)	$	(814	)	$	2,998	$	2,551
	Net income (loss)		$	(9,596	)	$	(517	)	$	1,973	$	2,578
	Basic earnings (loss) per share (3)		$	(0.27	)	$	(0.01	)	$	0.06	$	0.07
	Diluted earnings (loss) per share (3)		$	(0.27	)	$	(0.01	)	$	0.05	$	0.07
	Year Ended		First			Second			Third		Fourth
	31-Dec-13
				(1)			(1)		-2			(1), (2)
	Revenues		$	165,165		$	162,270		$	166,615	$	169,235
	Gross margin		$	15,083		$	19,916		$	26,391	$	18,326
	Income (loss) before income taxes		$	(6,044	)	$	(1,650	)	$	1,108	$	(7,591	)
	Net income (loss)		$	(3,949	)	$	(1,101	)	$	1,799	$	(5,290	)
	Basic earnings (loss) per share (3)		$	(0.12	)	$	(0.03	)	$	0.05	$	(0.15	)
	Diluted earnings (loss) per share (3)		$	(0.12	)	$	(0.03	)	$	0.05	$	(0.15	)
	(1) The assumed exercise of stock-based compensation awards for this period was not considered in the calculation of diluted earnings (loss) per share because the impact would have been anti-dilutive.
	(2) Includes charges related to non-cash interest associated with amortization of a debt discount of $1.6 million, $1.7 million, $1.7 million, and $1.7 million for the first, second, third and fourth quarter of 2014, respectively, and $1.5 million and $1.6 million for the third and fourth quarter of 2013, respectively.
	(3) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period.  Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
	(4) Includes charges for the first quarter of 2014 of approximately $9.4 million in connection with our settlement of a legal matter and $8.3 million for the fourth quarter of 2014 related to two additional legal settlements.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	a.  Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly owned by the Company.  We have eliminated all intercompany profits, transactions and balances.
Cash and Cash Equivalents	b.  Cash and Cash Equivalents - Cash and cash equivalents primarily include cash, tax-exempt debt instruments, commercial paper, and other short-term investments with original maturities of less than three months.
Accounts Receivable, net	c.  Accounts Receivable, net - Accounts receivable includes billed and unbilled amounts.  Billed receivables represent fees that are contractually due for services performed, net of contractual allowances (reflected as a reduction of revenue) and allowances for doubtful accounts (reflected as selling, general and administrative expenses). These combined allowances totaled $2.6 million and $2.0 million at December 31, 2014 and December 31, 2013, respectively. Unbilled receivables primarily represent fees recognized for monthly member utilization of fitness facilities under our SilverSneakers® fitness solution,  billed one month in arrears, and certain performance-based fees that  cannot be billed until after they are reconciled with the customer.  Historically, we have experienced minimal instances of customer non-payment and therefore consider our accounts receivable to be collectible; however, we provide reserves, when appropriate, for doubtful accounts and for contractual allowances (such as data reconciliation differences) on a specific identification basis.
Property and Equipment	d.  Property and Equipment - Property and equipment is carried at cost and includes expenditures that increase value or extend useful lives.  We recognize depreciation using the straight-line method over useful lives of three to seven years for computer software and hardware and four to seven years for furniture and other office equipment.  Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the life of the lease, which ranges from two to fifteen years.  Depreciation expense for the years ended December 31, 2014, 2013, and 2012 was $42.2 million, $40.1 million, and $39.1 million, respectively, including amortization of assets recorded under capital leases.
	Net computer software at December 31, 2014 and 2013 was $98.0 million and $99.1 million, respectively.  Depreciation expense related to computer software for the years ended December 31, 2014, 2013, and 2012 was $29.9 million, $26.5 million, and $24.9 million, respectively.
Other Assets	e.  Other Assets - Other assets consist primarily of cash convertible notes hedges, long-term investments, long-term customer incentives, and deferred loan costs net of accumulated amortization.
Intangible Assets	f.  Intangible Assets - Intangible assets subject to amortization include customer contracts, acquired technology, patents, distributor and provider networks, a perpetual license, and other intangible assets which we amortize on a straight-line basis over estimated useful lives ranging from three to 25 years.  We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable.
	Intangible assets not subject to amortization at December 31, 2014 and 2013 consist of a trade name of $29.0 million.  We review intangible assets not subject to amortization on an annual basis or more frequently whenever events or circumstances indicate that the assets might be impaired.  See Note 4 for further information on intangible assets.
Goodwill	g.  Goodwill - We recognize goodwill for the excess of the purchase price over the fair value of tangible and identifiable intangible net assets of businesses that we acquire.
	We review goodwill for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable.  We allocate goodwill to reporting units based on the reporting unit expected to benefit from the combination.
	We estimate the fair value of our reporting units using a combination of a discounted cash flow model and a market-based approach, and we reconcile the aggregate fair value of our reporting units to our consolidated market capitalization.
Contract Billings in Excess of Earned Revenue	h. Contract Billings in Excess of Earned Revenue - Contract billings in excess of earned revenue primarily represent performance-based fees subject to refund that we have not recognized as revenues because either (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that we are not currently meeting performance targets.
	i. Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank.
Accounts Payable Policy [Text Block]	i. Accounts Payable - Accounts payable consists of short-term trade obligations and includes cash overdrafts attributable to disbursements not yet cleared by the bank.
Income Taxes	j. Income Taxes - We file a consolidated federal income tax return that includes all of our domestic wholly-owned subsidiaries.  Generally accepted accounting principles in the United States ("U.S. GAAP") generally require that we record deferred income taxes for the tax effect of differences between the book and tax bases of our assets and liabilities.  We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.
Revenue Recognition	k. Revenue Recognition - We recognize revenue as services are performed when persuasive evidence of an arrangement exists, collectability is reasonably assured, and amounts are fixed or determinable.
	Our fees are generally billed on a PMPM basis or upon member participation, such as the Healthways® SilverSneakers® fitness solution.  For PMPM fees, we generally determine our contract fees by multiplying the contractually negotiated PMPM rate by the number of members covered by our services during the month.  We typically set PMPM rates during contract negotiations with customers based on the value we expect our programs to create and a sharing of that value between the customer and the Company.  Some of our contracts place a portion of our fees at risk based on achieving certain performance metrics, cost savings, and/or clinical outcomes improvements ("performance-based").  Approximately 6% of revenues recorded during the year ended December 31, 2014 were performance-based of which 2% were subject to final reconciliation as of December 31, 2014.
	We generally bill our customers each month for the entire amount of the fees contractually due for the prior month's enrollment, which typically includes the amount, if any, that is performance-based and may be subject to refund should we not meet performance targets.  Fees for participation are typically billed in the month after the services are provided.  Deferred revenues arise from contracts that permit upfront billing and collection of fees covering the entire contractual service period, generally 12 months.  A limited number of our contracts provide for certain performance-based fees that cannot be billed until after they are reconciled with the customer.
	We recognize revenue as follows: (1) we recognize the fixed portion of PMPM fees and fees for service as revenue during the period we perform our services; and (2) we recognize performance-based revenue based on the most recent assessment of our performance, which represents the amount that the customer would legally be obligated to pay if the contract were terminated as of the latest balance sheet date.
	We generally assess our level of performance for our contracts based on medical claims and other data that the customer is contractually required to supply, interim assessments of achievement against performance targets, or metrics available from our operating platforms.  A minimum of four to nine months' data is typically required for us to measure performance.  In assessing our performance, we may include estimates such as medical claims incurred but not reported.  In addition, we may also provide reserves for contractual allowances (such as data reconciliation differences) as appropriate.
	If data is insufficient or incomplete to measure performance, or interim performance measures indicate that we are not meeting performance targets, we do not recognize performance-based fees subject to refund as revenues but instead record them in a current liability account entitled "contract billings in excess of earned revenue."  Only in the event we do not meet performance levels by the end of the measurement period, typically one year, are we contractually obligated to refund some or all of the performance-based fees.  We would only reverse revenues that we had already recognized if performance to date in the measurement period, previously above targeted levels, subsequently dropped below targeted levels.
	During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, we settle any performance-based fees and reconcile healthcare claims and clinical data.  As of December 31, 2014, cumulative performance-based revenues that have not yet been settled with our customers but that have been recognized in the current and prior years totaled approximately $26.0 million, all of which were based on actual data.  Data reconciliation differences, for which we provide contractual allowances until we reach agreement with respect to identified issues, can arise between the customer and us due to customer data deficiencies, omissions, and/or data discrepancies.
	Performance-related adjustments (including any amounts recorded as revenue that were ultimately refunded), changes in estimates, or data reconciliation differences may cause us to recognize or reverse revenue in a current fiscal year that pertains to services provided during a prior fiscal year.  During 2014, 2013 and 2012, we recognized a net increase in revenue of $7.9 million, $8.2 million, and $9.2 million that related to services provided prior to each respective year.
Earnings (Loss) Per Share
Share-Based Compensation	m.  Share-Based Compensation – We recognize all share-based payments to employees in the consolidated statements of operations over the required vesting period based on estimated fair values at the date of grant.  See Note 12 for further information on share-based compensation.
Derivative Instruments and Hedging Activities	n. Derivative Instruments and Hedging Activities – We use derivative instruments to manage risks related to interest expense, foreign currencies, and the cash convertible senior notes (as discussed in Note 6). We account for derivatives in accordance with Financial Accounting Standards Board ("FASB")  Accounting Standards Codification ("ASC") Topic 815, which establishes accounting and reporting standards requiring that certain derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally, changes in the derivative's fair value will be recognized currently in earnings unless specific hedge accounting criteria are met. As permitted under our master netting arrangements, the fair value amounts of our interest rate swaps and foreign currency options and/or forward contracts are presented on a net basis by counterparty in the consolidated balance sheets. See Note 7 for further information on derivative instruments and hedging activities.
Management Estimates	o. Management Estimates – In preparing our consolidated financial statements in conformity with U.S. GAAP, management must make estimates and assumptions that affect: (1) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements; and (2) the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill [Abstract]
Change in carrying amount of goodwill	The change in carrying amount of goodwill during the years ended December 31, 2012, 2013, and 2014 is shown below:
	(In thousands)
	Balance, December 31, 2011	$	335,392
	Ascentia purchase		3,303
	Balance, December 31, 2012		338,695
	Other adjustments		105
	Balance, December 31, 2013		338,800
	Other adjustments		—
	Balance, December 31, 2014	$	338,800

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Intangible Assets [Abstract]
Intangible assets subject to amortization	Intangible assets subject to amortization at December 31, 2014 consisted of the following:
	(In thousands)	Gross Carrying		Accumulated		Net
		Amount		Amortization
	Customer contracts	$	16,170	$	13,445	$	2,725
	Acquired technology		19,268		16,709		2,559
	Patents		24,711		17,486		7,225
	Distributor and provider networks		8,709		7,711		998
	Perpetual license to survey-based data		31,000		5,315		25,685
	Other		2,140		1,220		920
	Total	$	101,998	$	61,886	$	40,112
	Intangible assets subject to amortization at December 31, 2013 consisted of the following:
	(In thousands)	Gross Carrying		Accumulated		Net
		Amount		Amortization
	Customer contracts	$	59,574	$	51,512	$	8,062
	Acquired technology		29,431		25,589		3,842
	Patents		24,547		15,081		9,466
	Distributor and provider networks		8,709		7,190		1,519
	Perpetual license to survey-based data		30,000		3,986		26,014
	Other		5,077		3,867		1,210
	Total	$	157,338	$	107,225	$	50,113
Estimated future amortization expense	Intangible assets subject to amortization are being amortized over estimated useful lives ranging from three to 25 years.  Total amortization expense for the years ended December 31, 2014, 2013, and 2012, was $11.2 million, $12.7 million, and $12.6 million, respectively.  The following table summarizes the estimated amortization expense for each of the next five years and thereafter:
	(In thousands)
	Year ending December 31,
	2015	$	6,778
	2016		4,998
	2017		3,338
	2018		2,714
	2019		2,395
	2020 and thereafter		19,889
	Total	$	40,112

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Taxes [Abstract]
Components of income tax expense	Income tax expense is comprised of the following:
	(In thousands)	Year Ended December 31,
		2014			2013			2012
	Current taxes
	Federal	$	483		$	(1,311	)	$	(1,271	)
	State		269			741			774
	Foreign		1,316			1,693			1,754
	Deferred taxes
	Federal		(4,844	)		(5,842	)		4,803
	State		(1,938	)		(1,018	)		413
	Foreign		127			101			249
	Total	$	(4,587	)	$	(5,636	)	$	6,722
Significant components of net deferred tax liability	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  The following table sets forth the significant components of our net deferred tax liability as of December 31, 2013 and 2012:
	(In thousands)	31-Dec-13			31-Dec-12
	Deferred tax asset:
	Accruals and reserves	$	14,159		$	10,910
	Deferred compensation		3,933			6,597
	Share-based payments		10,703			12,213
	Net operating loss carryforwards		8,303			7,914
	Cash conversion derivative		3,553			—
	Other assets and liabilities		1,486			1,533
			42,137			39,167
	Valuation allowance		(3,630	)		(3,242	)
		$	38,507		$	35,925
	Deferred tax liability:
	Property and equipment	$	(44,740	)	$	(47,317	)
	Intangible assets		(13,418	)		(15,700	)
	Cash convertible notes hedges		(3,553	)		—
	Other assets and liabilities		(449	)		(122	)
			(62,160	)		(63,139	)
	Net deferred tax liability	$	(23,653	)	$	(27,214	)
	Net current deferred tax asset	$	9,667		$	8,839
	Net long-term deferred tax liability		(33,320	)		(36,053	)
		$	(23,653	)	$	(27,214	)
Difference between income tax expense computed using statutory federal income tax rate and effective rate	The difference between income tax expense computed using the statutory federal income tax rate and the effective rate is as follows:
		Year Ended December 31,
	(In thousands)	2013			2012			2011
	Statutory federal income tax	$	(4,962	)	$	5,161		$	(49,808	)
	Non-deductible goodwill impairment expense		—			—			61,785
	State income taxes, less federal income tax benefit		(669	)		453			1,520
	Permanent items		634			389			434
	Change in valuation allowance		388			285			972
	Prior year tax adjustments		140			263			150
	Uncertain tax position reversal		(1,137	)		—			—
	Other		(30	)		171			333
	Income tax expense (benefit)	$	(5,636	)	$	6,722		$	15,386
Changes in unrecognized tax benefits	(In thousands)
	Unrecognized tax benefits at December 31, 2012	$	1,348
	Decreases based upon a lapse of the applicable statute of limitations		(1,060	)
	Unrecognized tax benefits at December 31, 2013	$	288
	Decreases based upon tax positions related to prior years		(35	)
	Unrecognized tax benefits at December 31, 2014	$	253

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Long-Term Debt [Abstract]
Schedule of Debt [Table Text Block]	The Company's long-term debt consists of the following at December 31, 2014 and 2013:
	(In thousands)	31-Dec-14			31-Dec-13
	Cash Convertible Notes, net of unamortized discount	$	123,148		$	116,392
	CareFirst Convertible Note		20,000			20,000
	Fifth Amended Credit Agreement:
	Term Loan		97,500			110,000
	Revolver		4,950			3,625
	Capital lease obligations and other		6,127			1,905
			251,725			251,922
	Less: current portion		(20,613	)		(14,340	)
		$	231,112		$	237,582
Minimum annual principal payments and repayments of the revolving advances	The following table summarizes the minimum annual principal payments and repayments of the revolving advances under the Fifth Amended Credit Agreement, the Cash Convertible Notes, and the CareFirst Convertible Note for each of the next five years and thereafter:
	(In thousands)
	Year ending December 31,
	2014	$	12,500
	2015		17,500
	2016		20,000
	2017		63,625
	2018		150,000
	2019 and thereafter		20,000
	Total	$	283,625

Derivative_Investments_and_Hed1

Derivative Investments and Hedging Activities (Tables)	12 Months Ended
	Dec. 31, 2014
Derivative Investments and Hedging Activities [Abstract]
Effect of cash flow hedges on consolidated balance sheets	The following table shows the effect of our cash flow hedges on the consolidated balance sheets during the twelve months ended December 31, 2013 and 2012:
	(In thousands)	For the Twelve Months Ended
	Derivatives in Cash Flow Hedging Relationships	31-Dec-13				31-Dec-12
	(Gain) loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect		$	(332	)		$	2,029
	Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect		$	(1,916	)		$	(3,302	)
Gains and Losses on Cash Convertible Notes Hedges and Cash Conversion Derivative	The gains and losses resulting from changes in the fair values of the Cash Conversion Derivative and the Cash Convertible Notes Hedges are reported in the consolidated statements of comprehensive income (loss) as follows:
		Twelve Months Ended
	(In thousands)	31-Dec-13				31-Dec-12				Statements of Comprehensive Income (Loss) Classification
	Cash Convertible Notes Hedges:
	Net unrealized loss		$	(8,984	)		$	—		Selling, general and administrative expense
	Cash Conversion Derivative:
	Net unrealized gain		$	8,984			$	—		Selling, general and administrative expense
Fair values of derivative instruments	The estimated gross fair values of derivative instruments at December 31, 2013 and December 31, 2012, excluding the impact of netting derivative assets and liabilities when a legally enforceable master netting agreement exists, were as follows:
			31-Dec-13										31-Dec-12
	(In thousands)		Foreign currency exchange contracts				Interest rate swap agreements				Cash Convertible Notes Hedges and Cash Conversion Derivative		Foreign currency exchange contracts		Interest rate swap agreements
	Assets:
	Derivatives not designated as hedging instruments:
	Other current assets		$	178			$	—			$	—	$	73	$	—
	Other assets			—				—				27,766		—		—
	Total assets		$	178			$	—			$	27,766	$	73	$	—
	Liabilities:
	Derivatives not designated as hedging instruments:
	Accrued liabilities		$	67			$	—			$	—	$	255	$	—
	Other long-term liabilities			—				—				27,766		—		—
	Derivatives designated as hedging instruments:
	Accrued liabilities			—				—				—		—		1,742
	Other long-term liabilities			—				505				—		—		1,221
	Total liabilities		$	67			$	505			$	27,766	$	255	$	2,963

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements [Abstract]
Assets and liabilities measured at fair value on a recurring basis	The following tables present our assets and liabilities measured at fair value on a recurring basis at December 31, 2014 and December 31, 2013:
	(In thousands)	Level 2		Level 3		Gross Fair			Netting (1)			Net Fair
	31-Dec-14					Value						Value
	Assets:
	Foreign currency exchange contracts	$	477	$	—	$	477		$	(111	)	$	366
	Cash Convertible Notes Hedges		—		48,025		48,025			—			48,025
	Liabilities:
	Foreign currency exchange contracts	$	111	$	—	$	111		$	(111	)	$	—
	Interest rate swap agreements		395		—		395			—			395
	Cash Conversion Derivative		—		48,025		48,025			—			48,025
	(In thousands)	Level 2		Level 3		Gross Fair			Netting (1)			Net Fair
	31-Dec-13					Value						Value
	Assets:
	Foreign currency exchange contracts	$	178	$	—	$	178		$	(57	)	$	121
	Cash Convertible Notes Hedges		—		27,766		27,766			—			27,766
	Liabilities:
	Foreign currency exchange contracts	$	67	$	—	$	67		$	(57	)	$	10
	Interest rate swap agreements		505		—		505			—			505
	Cash Conversion Derivative		—		27,766		27,766			—			27,766
	(1) This column reflects the impact of netting derivative assets and liabilities by counterparty when a legally enforceable master netting agreement exists.
Level 3 Financial Instruments [Table Text Block]
	The following table presents our financial instruments measured at fair value on a recurring basis using unobservable inputs (Level 3):
	(In thousands)	Balance at December 31, 2012		Purchases of Level 3 Instruments		Issuances of Level 3 Instruments			Gains/(Losses) included in Earnings			Balance at December 31, 2013
	Cash Convertible Notes Hedges	$	—	$	36,750	$	—		$	(8,984	)	$	27,766
	Cash Conversion Derivative		—		—		(36,750	)		8,984			(27,766	)

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Summary of future minimum lease payments under all capital leases and non-cancelable operating leases	The following table summarizes our future minimum lease payments under all capital leases and non-cancelable operating leases for each of the next five years and thereafter:
	(In thousands)	Capital			Operating
	Year ending December 31,	Leases			Leases
	2015	$	1,709		$	13,724
	2016		1,442			13,443
	2017		1,258			13,006
	2018		365			13,282
	2019		—			12,553
	2020 and thereafter		—			23,903
	Total minimum lease payments	$	4,774		$	89,911
	Less: amount representing interest		(238	)
	Present value of minimum lease payments		4,536
	Less: current portion		(1,576	)
		$	2,960

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Share-Based Compensation [Abstract]
Allocated share-based compensation costs	Following are certain amounts recognized in the consolidated statements of operations for share-based compensation arrangements for the years ended December 31, 2014, 2013, and 2012.  We did not capitalize any share-based compensation costs during these periods.
		Year Ended
		December 31,			December 31,			December 31,
	(In millions)	2014			2013			2012
	Total share-based compensation	$	8.3		$	7.1			$	6.4
	Share-based compensation included in cost of services		3.8			2.9				3
	Share-based compensation included in selling, general and administrative expenses		4.5			4.2				3.4
	Total income tax benefit recognized		3.3			2.8				2.5
Weighted average grant-date fair values of options and the weighted average assumptions used	The following table sets forth the weighted average grant-date fair values of options and the weighted average assumptions we used to develop the fair value estimates under each of the option valuation models for the years ended December 31, 2014, 2013 and 2012:
		Year Ended December 31,
		2014			2013				2012
	Weighted average grant-date fair value of options per share	$	9.05		$	7.29			$	4.01
	Assumptions:
	Expected volatility		54.6	%		53.8	%			54.4	%
	Expected dividends		—			—				—
	Expected term (in years)		4.7			5.1				5.1
	Risk-free rate		2.4	%		1.9	%			2	%
Summary of stock option activity	A summary of option activity as of December 31, 2014 and the changes during the year then ended is presented below:
	Options	Shares (thousands)			Weighted				Weighted Average			Aggregate Intrinsic Value (thousands)
					Average Exercise				Remaining
					Price				Contractual
					Per Share				Term
	Outstanding at January 1, 2014		4,325		$	15.09
	Granted		98			16.6
	Exercised		(224	)		12.75
	Forfeited		(80	)		12.87
	Expired		(555	)		29.94
	Outstanding at December 31, 2014		3,564		$	13.01				6.4		$	27,511
	Exercisable at December 31, 2014		1,942		$	14.26				5.5		$	13,940
Summary of restricted stock, restricted stock units , and performance share units ("nonvested shares")	The following table sets forth a summary of our nonvested shares as of December 31, 2014 as well as activity during the year then ended.  The total grant-date fair value of shares vested during the years ended December 31, 2014, 2013, and 2012 was $2.5 million, $3.1 million, and $3.6 million, respectively.
		Restricted Stock Units							Performance-Based Stock Units
	Nonvested Shares	Shares (thousands)			Weighted Average Grant Date Fair Value Per Share				Shares (thousands)			Weighted Average Grant Date Fair Value Per Share
	Nonvested at January 1, 2014		841		$	10.44				—		$	—
	Granted		475			16.72				341			14.77
	Vested		(231	)		10.83				—			—
	Forfeited		(38	)		11.8				—			—
	Nonvested at December 31, 2014		1,047		$	13.15				341		$	14.77

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings (Loss) Per Share [Abstract]
Reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share	The following is a reconciliation of the numerator and denominator of basic and diluted earnings (loss) per share for the years ended December 31, 2014, 2013, and 2012:
	(In thousands except per share data)	Year Ended December 31,
	Numerator:	2014			2013			2012
	Net income (loss)	$	(5,561	)	$	(8,541	)	$	8,024
	Denominator:
	Shares used for basic earnings (loss) per share		35,302			34,489			33,597
	Effect of dilutive stock options and restricted stock units outstanding:
	Non-qualified stock options (1)		—			—			37
	Restricted stock units (1)		—			—			202
	Shares used for diluted earnings (loss) per share (1)		35,302			34,489			33,836
	Earnings (loss) per share:
	Basic	$	(0.16	)	$	(0.25	)	$	0.24
	Diluted (1)	$	(0.16	)	$	(0.25	)	$	0.24
	Dilutive securities outstanding not included in the computation of earnings (loss) per share because their effect is anti-dilutive:
	Non-qualified stock options		1,865			3,234			4,926
	Restricted stock units		453			334			193
	Performance-based stock units		20			—			—
	Warrants related to Cash Convertible Notes		7,707			7,707			—
	CareFirst Convertible Note		892			892			—
	CareFirst Warrants		87			—			—
	(1) The assumed exercise of stock-based compensation awards for the years ended December 31, 2014 and December 31, 2013 was not considered because the impact would be anti-dilutive.

Accumulated_OCI_Tables

Accumulated OCI (Tables)	12 Months Ended
	Dec. 31, 2014
Accumulated OCI [Abstract]
Schedule of changes in accumulated other comprehensive income (AOCI)	The following tables summarize the changes in accumulated OCI, net of tax, for the twelve months ended December 31, 2014 and 2013:
	(In thousands)		Net Change in Fair Value of Interest Rate Swaps				Foreign Currency Translation Adjustments				Total
	Accumulated OCI, net of tax, as of January 1, 2014		$	(513	)		$	106			$	(407	)
	Other comprehensive income (loss) before reclassifications, net of tax			(135	)			(1,812	)			(1,947	)
	Amounts reclassified from accumulated OCI, net of tax			306				—				306
	Net increase (decrease) in other comprehensive income (loss), net of tax			171				(1,812	)			(1,641	)
	Accumulated OCI, net of tax, as of December 31, 2014		$	(342	)		$	(1,706	)		$	(2,048	)
	(In thousands)		Net Change in Fair Value of Interest Rate Swaps				Foreign Currency Translation Adjustments				Total
	Accumulated OCI, net of tax, as of January 1, 2013		$	(1,790	)		$	861			$	(929	)
	Other comprehensive income (loss) before reclassifications, net of tax			189				(755	)			(566	)
	Amounts reclassified from accumulated OCI, net of tax			1,088				—				1,088
	Net increase (decrease) in other comprehensive income (loss), net of tax			1,277				(755	)			522
	Accumulated OCI, net of tax, as of December 31, 2013		$	(513	)		$	106			$	(407	)
Reclassification out of Accumulated Other Comprehensive Income	The following table provides details about reclassifications out of accumulated OCI for the years ended December 31, 2014 and 2013:
		Year Ended December 31,								Statement of Comprehensive Income
	(In thousands)	2014				2013				(Loss) Classification
	Interest rate swaps		$	507			$	1,916		Interest expense
				(201	)			(828	)	Income tax benefit
			$	306			$	1,088		Net of tax
	See Note 7 for further discussion of our interest rate swaps.

Quarterly_Financial_Informatio1

Quarterly Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information (unaudited) [Abstract]
Schedule of quarterly financial information	18	Quarterly Financial Information (unaudited)
	(In thousands, except per share data)
	Year Ended		First			Second			Third		Fourth
	31-Dec-14
				(1), (2), (4)			(1), (2)		-2		(2), (4)
	Revenues		$	176,777		$	180,613		$	185,656	$	199,136
	Gross margin		$	19,257		$	24,533		$	27,314	$	35,058
	Income (loss) before income taxes		$	(14,884	)	$	(814	)	$	2,998	$	2,551
	Net income (loss)		$	(9,596	)	$	(517	)	$	1,973	$	2,578
	Basic earnings (loss) per share (3)		$	(0.27	)	$	(0.01	)	$	0.06	$	0.07
	Diluted earnings (loss) per share (3)		$	(0.27	)	$	(0.01	)	$	0.05	$	0.07
	Year Ended		First			Second			Third		Fourth
	31-Dec-13
				(1)			(1)		-2			(1), (2)
	Revenues		$	165,165		$	162,270		$	166,615	$	169,235
	Gross margin		$	15,083		$	19,916		$	26,391	$	18,326
	Income (loss) before income taxes		$	(6,044	)	$	(1,650	)	$	1,108	$	(7,591	)
	Net income (loss)		$	(3,949	)	$	(1,101	)	$	1,799	$	(5,290	)
	Basic earnings (loss) per share (3)		$	(0.12	)	$	(0.03	)	$	0.05	$	(0.15	)
	Diluted earnings (loss) per share (3)		$	(0.12	)	$	(0.03	)	$	0.05	$	(0.15	)
	(1) The assumed exercise of stock-based compensation awards for this period was not considered in the calculation of diluted earnings (loss) per share because the impact would have been anti-dilutive.
	(2) Includes charges related to non-cash interest associated with amortization of a debt discount of $1.6 million, $1.7 million, $1.7 million, and $1.7 million for the first, second, third and fourth quarter of 2014, respectively, and $1.5 million and $1.6 million for the third and fourth quarter of 2013, respectively.
	(3) We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period.  Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.
	(4) Includes charges for the first quarter of 2014 of approximately $9.4 million in connection with our settlement of a legal matter and $8.3 million for the fourth quarter of 2014 related to two additional legal settlements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounts Receivable, Net [Abstract]
Total contractual allowances and allowance for doubtful accounts	$2,600,000	$2,000,000
Property, Plant and Equipment [Line Items]
Property and equipment, net	165,696,000	158,198,000
Depreciation	42,200,000	40,100,000	39,100,000
Finite-Lived Intangible Assets [Line Items]
Intangible assets not subject to amortization	29,000,000	29,000,000
Revenue Recognition [Abstract]
Percentage of performance based revenues (in hundredths)	6.00%
Percentage of performance based revenues subject to final reconciliation (in hundredths)	2.00%
Cumulative performance-based revenues not settled yet but recognized	26,000,000
Net increase in revenue relating to services provided in prior periods	7,900,000	8,200,000	9,200,000
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	3 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	25 years
Computer Software and Hardware [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Computer Software and Hardware [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Furniture and Other Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	4 years
Furniture and Other Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful life	2 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful life	15 years
Computer Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, net	98,000,000	99,100,000
Depreciation	$29,900,000	$26,500,000	$24,900,000

Goodwill_Details

Goodwill (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill Rollforward
Goodwill, net	$338,800,000	$338,695,000	$335,392,000
Ascentia purchase			3,303,000
Other adjustments	0	105,000
Goodwill, net	338,800,000	338,800,000	338,695,000
Business Acquisition [Line Items]
Goodwill, Gross	521,100,000	521,100,000
Goodwill, Impaired, Accumulated Impairment Loss	182,400,000	182,400,000
Ascentia [Member]
Business Acquisition [Line Items]
Cash payment for the acquisition			5,500,000
Unregistered shares of common stock issued (in shares)			14,409
Value of common stock issued			$100,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$101,998,000	$157,338,000
Accumulated Amortization	61,886,000	107,225,000
Total	40,112,000	50,113,000
Amortization expense	11,200,000	12,700,000	12,600,000
Estimated future amortization expense [Abstract]
2015	6,778,000
2016	4,998,000
2017	3,338,000
2018	2,714,000
2019	2,395,000
2020 and thereafter	19,889,000
Total	40,112,000	50,113,000
Intangible assets not subject to amortization	29,000,000	29,000,000
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	3 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life	25 years
Customer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	16,170,000	59,574,000
Accumulated Amortization	13,445,000	51,512,000
Total	2,725,000	8,062,000
Estimated future amortization expense [Abstract]
Total	2,725,000	8,062,000
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	19,268,000	29,431,000
Accumulated Amortization	16,709,000	25,589,000
Total	2,559,000	3,842,000
Estimated future amortization expense [Abstract]
Total	2,559,000	3,842,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	24,711,000	24,547,000
Accumulated Amortization	17,486,000	15,081,000
Total	7,225,000	9,466,000
Estimated future amortization expense [Abstract]
Total	7,225,000	9,466,000
Distributor and Provider Networks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	8,709,000	8,709,000
Accumulated Amortization	7,711,000	7,190,000
Total	998,000	1,519,000
Estimated future amortization expense [Abstract]
Total	998,000	1,519,000
Perpetual License to Survey-Based Data [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	31,000,000	30,000,000
Accumulated Amortization	5,315,000	3,986,000
Total	25,685,000	26,014,000
Estimated future amortization expense [Abstract]
Total	25,685,000	26,014,000
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,140,000	5,077,000
Accumulated Amortization	1,220,000	3,867,000
Total	920,000	1,210,000
Estimated future amortization expense [Abstract]
Total	$920,000	$1,210,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2032	Dec. 31, 2017
Current taxes [Abstract]
Federal	$483,000	($1,311,000)	($1,271,000)
State	269,000	741,000	774,000
Foreign	1,316,000	1,693,000	1,754,000
Deferred taxes [Abstract]
Federal	-4,844,000	-5,842,000	4,803,000
State	-1,938,000	-1,018,000	413,000
Foreign	127,000	101,000	249,000
Income tax expense	-4,587,000	-5,636,000	6,722,000
Income (Loss) from Continuing Operations before Income Taxes, Foreign	5,200,000	4,500,000	4,800,000
Deferred tax asset [Abstract]
Accruals and reserves	17,769,000	14,159,000
Deferred compensation	4,372,000	3,933,000
Share-based payments	9,368,000	10,703,000
Net operating loss carryforwards	7,167,000	8,303,000
Deferred Tax Asset on Cash Conversion Derivative and Cash Convertible Notes Hedges, respectively	4,459,000	3,553,000
Other deferred tax assets	3,124,000	1,486,000
Deferred tax assets, Gross	46,259,000	42,137,000
Valuation allowance	-3,836,000	-3,630,000
Total	42,423,000	38,507,000
Deferred tax liability [Abstract]
Property and equipment	-44,832,000	-44,740,000
Intangible assets	-11,778,000	-13,418,000
Deferred Tax Liability on Cash convertible notes hedge and cash conversion derivative, respectively	-4,459,000	-3,553,000
Other liabilities	-1,119,000	-449,000
Total	-62,188,000	-62,160,000
Net deferred tax liability	-19,765,000	-23,653,000
Net current deferred tax asset	13,118,000	9,667,000
Net long-term deferred tax liability	-32,883,000	-33,320,000
Tax effect on interest rate swap agreements	44,000	972,000	493,000
Difference between income tax expense computed using statutory federal income tax rate and effective rate [Abstract]
Statutory federal income tax	-3,552,000	-4,962,000	5,161,000
State income taxes, less federal income tax benefit	-456,000	-669,000	453,000
Permanent items	137,000	634,000	389,000
Change in valuation allowance	206,000	388,000	285,000
Prior year tax adjustments	-42,000	140,000	263,000
Uncertain tax position reversal	0	-1,137,000	0
State income tax credits	-650,000	0	0
Net impact of foreign earnings	-218,000	-175,000	39,000
Other	-12,000	145,000	132,000
Income tax expense	-4,587,000	-5,636,000	6,722,000
Income Tax Contingency [Line Items]
Unrecognized tax benefits that affect our effective tax rate	300,000	300,000
Reduction resulting from lapse of applicable statute of Limitations		1,100,000
Changes in unrecognized tax benefits [Roll Forward]
Balance, beginning of period	288,000	1,348,000
Decreases based upon tax positions related to prior years		-1,060,000
Decreases based upon a lapse of the applicable statute of limitations	-35,000
Balance, end of period	253,000	288,000	1,348,000
Undistributed Earnings of Foreign Subsidiaries	14,900,000
International [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	14,500,000
Changes in unrecognized tax benefits [Roll Forward]
Open tax year	2011
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	7,300,000
Operating loss carryforwards, expiration dates	31-Dec-21
Changes in unrecognized tax benefits [Roll Forward]
Open tax year	2011
State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$17,200,000
Operating loss carryforwards, expiration dates				31-Dec-32	31-Dec-17
Changes in unrecognized tax benefits [Roll Forward]
Open tax year	2011

LongTerm_Debt_Table_Details

Long-Term Debt, Table (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt, Long-term and Short-term, Combined Amount [Abstract]
Debt, Long-term and Short-term, Combined Amount	$251,725	$251,922
Long-term Debt	231,112	237,582
Short-term Debt	-20,613	-14,340
Cash Convertible Notes, net of unamortized discount
Debt, Long-term and Short-term, Combined Amount [Abstract]
Debt, Long-term and Short-term, Combined Amount	123,148	116,392
CareFirst Convertible Note [Member]
Debt, Long-term and Short-term, Combined Amount [Abstract]
Debt, Long-term and Short-term, Combined Amount	20,000	20,000
Term Loan Facility [Member]
Debt, Long-term and Short-term, Combined Amount [Abstract]
Debt, Long-term and Short-term, Combined Amount	97,500	110,000
Revolver
Debt, Long-term and Short-term, Combined Amount [Abstract]
Debt, Long-term and Short-term, Combined Amount	4,950	3,625
Capital lease obligations and other
Debt, Long-term and Short-term, Combined Amount [Abstract]
Debt, Long-term and Short-term, Combined Amount	$6,127	$1,905

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 01, 2018	Jul. 16, 2013	Oct. 01, 2019	Oct. 01, 2013
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	5.66%
Amortization of debt discount	$6,757,000	$3,140,000	$0
Debt Instrument, Unamortized Discount	26,900,000	33,600,000
Deferred Finance Costs, Gross					3,939,543
Interest Rate for Notes					1.50%
Aggregate Principal of convertible notes					150,000,000
Payments for Hedge, Financing Activities	0	36,750,000	0
Warrants Strike Price	$25.95
Minimum annual principal payments and repayments of the revolving advances [Abstract]
2015	17,500,000
2016	20,000,000
2017	64,950,000
2018	150,000,000
2019	20,000,000
2020 and thereafter	0
Total	272,450,000
Conversion price premium percentage	60.00%
Debt Instrument, Unamortized Discount	26,900,000	33,600,000
Cash Convertible Notes [Member]
Debt Instrument [Line Items]
Notes, Issuance Date					16-Jul-13
Debt Instrument, Maturity Date				1-Jul-18
Debt Instrument, Convertible, Conversion Ratio	51.38
Debt Instrument, Unamortized Discount					36,750,000
Aggregate Principal of convertible notes	150,000,000
Debt Instrument, Convertible, Conversion Price					$19.46
Payments for Hedge, Financing Activities					36,750,000
Initial Conversion rate					$19.46
Minimum annual principal payments and repayments of the revolving advances [Abstract]
Debt Instrument, Carrying Amount	123,100,000
Debt Instrument, Unamortized Discount					36,750,000
CareFirst Convertible Note [Member]
Debt Instrument [Line Items]
Notes, Issuance Date							1-Oct-13
Date of Registration Rights Agreement							1-Oct-13
Debt Instrument, Maturity Date						1-Oct-19
Interest Rate for Notes							4.75%
Aggregate Principal of convertible notes	$20,000,000						$20,000,000
Debt Instrument, Convertible, Conversion Price							$22.41
Initial Conversion rate							$22.41
Minimum annual principal payments and repayments of the revolving advances [Abstract]
CareFirst Warrant Shares Maximum							1,600,000
CareFirst Warrant Shares for one year period							400,000
CareFirst Warrants Outstanding	190,683
Warrants Weighted Average Exercise Price	$16.92

LongTerm_Debt_Line_of_Credit_a

Long-Term Debt, Line of Credit and Term Loan (Details) (USD $)	0 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jun. 08, 2017	Dec. 31, 2014
LIBOR [Member]
Line of Credit Facility [Line Items]
Basis spread on variable rate increased (in hundredths)		0.0025
Fifth Amended Credit Agreement [Member]
Line of Credit Facility [Line Items]
Initiation date		8-Jun-12
Maximum borrowing capacity		200
Expiration date		8-Jun-17
Amount outstanding		97.5
Availability under the revolving credit facility under most restrictive covenant		95.9
Interest rate description		Borrowings under the Fifth Amended Credit Agreement generally bear interest at variable rates based on a margin or spread in excess of either (1) the one-month, two-month, three-month or six-month rate (or with the approval of affected lenders, nine-month or twelve-month rate) for Eurodollar deposits ("LIBOR") or (2) the greatest of (a) the SunTrust Bank prime lending rate, (b) the federal funds rate plus 0.50%, and (c) one-month LIBOR plus 1.00% (the "Base Rate"), as selected by the Company. The LIBOR margin varies between 1.75% and 3.00%, and the Base Rate margin varies between 0.75% and 2.00%, depending on our leverage ratio. On February 5, 2013, we entered into a First Amendment to the Fifth Amended Credit Agreement, which included, among other things, a temporary increase in the LIBOR and Base Rate margins of 0.25%. The increased margins are effective through December 31, 2013 and apply only in the event that our total funded debt to EBITDA ratio is greater than or equal to 3.50 to 1.00.
Commitment fee description		The Fifth Amended Credit Agreement also provides for an annual fee ranging between 0.30% and 0.50% of the unused commitments under the revolving credit facility.
Letters of Credit Sub Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity		75
Swingline Sub Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity		20
Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Terms of periodic payments	We are required to repay outstanding revolving loans under the revolving credit facility in full on June 8, 2017. We are required to repay term loans in quarterly principal installments aggregating (1) 1.250% of the original aggregate principal amount of the term loans during each of the eight quarters beginning with the quarter ended September 30, 2012, (2) 1.875% of the original aggregate principal amount of the term loans during each of the next four quarters beginning with the quarter ending September 30, 2014, and (3) 2.500% of the original aggregate principal amount of the term loans during each of the remaining quarters prior to maturity on June 8, 2017, at which time the entire unpaid principal balance of the term loans is due and payable.
Maturity date		8-Jun-17
Uncommitted Incremental Accordion Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity		100

Derivative_Investments_and_Hed2

Derivative Investments and Hedging Activities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Derivatives, Fair Value [Line Items]
Debt Instrument, Unamortized Discount	$26,900,000	$33,600,000
Lower variable interest rate range (in hundredths)	0.69%
Higher variable interest rate range (in hundredths)	1.48%
Current notional amount	125,000,000
Fair Values of Derivative Instruments [Abstract]
Liabilities	48,025,000
Reclassification of net losses on interest rate swap agreements from accumulated OCI to interest expense within the next 12 months	300,000
Derivatives in Cash Flow Hedging Relationships [Abstract]
(Gain) loss related to effective portion of derivatives recognized in accumulated OCI, gross of tax effect	292,000	-332,000
Loss related to effective portion of derivatives reclassified from accumulated OCI to interest expense, gross of tax effect	-507,000	-1,916,000
Note Hedges and Conversions [Member] | Other Noncurrent Assets [Member] | Selling, General and Administrative Expenses [Member]
Fair Values of Derivative Instruments [Abstract]
Derivative, Gain on Derivative/Hedge	20,259,000
Derivative, Loss on Derivative/Hedge		-8,984,000
Interest Rate Swap Agreements [Member] | Other Current Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	0
Interest Rate Swap Agreements [Member] | Derivatives Designated as Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Notional amount effective in future	75,000,000
Fair Values of Derivative Instruments [Abstract]
Liabilities	395,000	505,000
Interest Rate Swap Agreements [Member] | Derivatives Designated as Hedging Instruments [Member] | Other Long-Term Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	395,000	505,000
Interest Rate Swap Agreements [Member] | Derivatives Designated as Hedging Instruments [Member] | Effective in November 2013 [Member]
Derivatives, Fair Value [Line Items]
Notional amount effective in future	0
Interest Rate Swap Agreements [Member] | Derivatives Designated as Hedging Instruments [Member] | Effective in 2015 [Member]
Derivatives, Fair Value [Line Items]
Notional amount effective in future	50,000,000
Interest Rate Swap Agreements [Member] | Derivatives Not Designated as Hedging Instruments [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	0	0
Interest Rate Swap Agreements [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Current Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets		0
Interest Rate Swap Agreements [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Accrued Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	0	0
Interest Rate Swap Agreements [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Long-Term Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	0	0
Interest Rate Swap Agreements [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Noncurrent Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	0	0
Foreign Currency Exchange Contracts [Member] | Derivatives Designated as Hedging Instruments [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	111,000	67,000
Foreign Currency Exchange Contracts [Member] | Derivatives Designated as Hedging Instruments [Member] | Other Long-Term Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	0	0
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instruments [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	477,000	178,000
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Current Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	477,000	178,000
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Accrued Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	111,000	67,000
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Long-Term Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	0	0
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Noncurrent Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	0	0
Foreign Currency Exchange Contracts [Member] | Forward Contracts [Member] | Derivatives Not Designated as Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Notional Amount	24,700,000
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	48,025,000
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Other Current Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	0
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Other Long-Term Liabilities [Member] | Selling, General and Administrative Expenses [Member]
Fair Values of Derivative Instruments [Abstract]
Derivative, Gain on Derivative/Hedge		8,984,000
Derivative, Loss on Derivative/Hedge	-20,259,000
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Derivatives Designated as Hedging Instruments [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	48,025,000	27,766,000
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Derivatives Designated as Hedging Instruments [Member] | Other Long-Term Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	0	0
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Derivatives Not Designated as Hedging Instruments [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	48,025,000	27,766,000
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Current Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets		0
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Accrued Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	0	0
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Long-Term Liabilities [Member]
Fair Values of Derivative Instruments [Abstract]
Liabilities	48,025,000	27,766,000
Cash Convertible Notes Hedges and Cash Conversion Derivative [Member] | Note Hedges and Conversions [Member] | Derivatives Not Designated as Hedging Instruments [Member] | Other Noncurrent Assets [Member]
Fair Values of Derivative Instruments [Abstract]
Assets	48,025,000	27,766,000
Embedded Derivative Financial Instruments [Member] | Derivatives Designated as Hedging Instruments [Member]
Derivatives, Fair Value [Line Items]
Debt Instrument, Unamortized Discount	$36,750,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 16, 2013	Dec. 31, 2012	Dec. 31, 2011
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	$48,025,000
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Cash and cash equivalents	1,765,000	2,584,000		1,759,000	864,000
Aggregate Principal of convertible notes			150,000,000
Cash Convertible Notes Hedge [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	27,766,000
Purchases into Level 3	0
Gains/ (Losses) included in Earnings	20,259,000
Balance at end of period	48,025,000
Fifth Amended Credit Facility [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Debt Instrument, Fair Value	101,900,000
Debt Instrument, Carrying Amount	102,500,000
Cash Convertible Notes [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Debt Instrument, Fair Value	148,100,000
Debt Instrument, Carrying Amount	123,100,000
Cash Conversion Derivative [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	-27,766,000
Issuances into Level 3	0
Gains/ (Losses) included in Earnings	-20,259,000
Balance at end of period	-48,025,000
CareFirst Convertible Note [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Debt Instrument, Fair Value	20,000,000
Debt Instrument, Carrying Amount	20,000,000
Recurring [Member] | Foreign Exchange Contract [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Liability	-111,000	-57,000
Derivative Asset, Fair Value, Amount Not Offset Against Collateral	366,000	121,000
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Asset	-111,000	-57,000
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	0	10,000
Recurring [Member] | Foreign Exchange Contract [Member] | Level 2 [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	477,000	178,000
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	111,000	67,000
Recurring [Member] | Foreign Exchange Contract [Member] | Level 3 [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	0	0
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	0	0
Recurring [Member] | Foreign Exchange Contract [Member] | Gross Fair Value [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	477,000	178,000
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	111,000	67,000
Recurring [Member] | Interest Rate Swap [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Asset	0	0
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	395,000	505,000
Recurring [Member] | Interest Rate Swap [Member] | Level 2 [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	395,000	505,000
Recurring [Member] | Interest Rate Swap [Member] | Level 3 [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	0	0
Recurring [Member] | Interest Rate Swap [Member] | Gross Fair Value [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	395,000	505,000
Recurring [Member] | Cash Convertible Notes Hedge [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Liability	0	0
Derivative Asset, Fair Value, Amount Not Offset Against Collateral	48,025,000	27,766,000
Recurring [Member] | Cash Convertible Notes Hedge [Member] | Level 2 [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	0	0
Recurring [Member] | Cash Convertible Notes Hedge [Member] | Level 3 [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	48,025,000	27,766,000
Recurring [Member] | Cash Convertible Notes Hedge [Member] | Gross Fair Value [Member]
Assets [Abstract]
Derivative Asset, Fair Value, Gross Asset	48,025,000	27,766,000
Recurring [Member] | Cash Conversion Derivative [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Asset	0	0
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	48,025,000	27,766,000
Recurring [Member] | Cash Conversion Derivative [Member] | Level 2 [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	0	0
Recurring [Member] | Cash Conversion Derivative [Member] | Level 3 [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	48,025,000	27,766,000
Recurring [Member] | Cash Conversion Derivative [Member] | Gross Fair Value [Member]
Liabilities [Abstract]
Derivative Liability, Fair Value, Gross Liability	$48,025,000	$27,766,000

Other_LongTerm_Liabilities_Det

Other Long-Term Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Other Long-Term Liabilities [Abstract]
Vested amounts under the non-qualified deferred compensation plan	$7.40	$6.80
Current portions of the non-qualified deferred compensation plan	0.5	1
Estimated future plan payments under non-qualified deferred compensation plan [Abstract]
2015	0.5
2016	1.2
2017	0.3
2018	0.3
2019	0.1
Accrued performance cash amount	0.9	0
Accrued performance cash amount, current portion	$0	$0

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	0 Months Ended	1 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Feb. 05, 2015	Jan. 31, 2015	Apr. 30, 2014	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Legal Settlement Amount paid in April 2014			$4
Legal Settlement Amount due January 2015		5.5
Junk Fax Prevention Act Lawsuit [Abstract]
Junk Fax Prevention Act Lawsuit Damages being sought				5
Contractual Commitment [Abstract]
Minimum remaining contractual cash obligations				34.5
Total minimum payments required under outsourcing agreement over remaining term				133.3
Estimate of remaining payments pursuant to outsourcing agreement				276.3
Loss Contingency, Settlement [Abstract]
Loss Contingency, Settlement Agreement, Date	4-Feb-15
Loss Contingency, Settlement Agreement, Counterparty's Name				Plastipak Packaging, Inc.
Litigation Settlement [Abstract]
Plastipak Legal Settlement				$7.20

Leases_Details

Leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Leased Assets [Line Items]
Lease expiration date	1-Feb-22
Operating lease term	15 years
Rent expense	$13,200,000	$12,900,000	$12,900,000
Tenant improvement allowance	10,700,000
Future minimum lease payments under capital leases [Abstract]
2015	1,709,000
2016	1,442,000
2017	1,258,000
2018	365,000
2019	0
2020 and thereafter	0
Total minimum lease payments	4,774,000
Less amount representing interest	-238,000
Present value of minimum lease payments	4,536,000
Less current portion	-1,576,000
Future minimum lease payments, net of current portion	2,960,000
Future minimum lease payments under operating leases [Abstract]
2015	13,724,000
2016	13,443,000
2017	13,006,000
2018	13,282,000
2019	12,553,000
2020 and thereafter	23,903,000
Total minimum lease payments	89,911,000
Minimum [Member]
Operating Leased Assets [Line Items]
Lease expiration date	30-Jun-15
Maximum [Member]
Operating Leased Assets [Line Items]
Lease expiration date	1-Dec-21
Corporate Headquarters and Call Center [Member]
Operating Leased Assets [Line Items]
Area of leased property (in square feet)	264,000
Corporate Headquarters and Call Center [Member] | Minimum [Member]
Operating Leased Assets [Line Items]
Rent expense	4,300,000
Corporate Headquarters and Call Center [Member] | Maximum [Member]
Operating Leased Assets [Line Items]
Rent expense	$6,600,000
Other Call Center Locations [Member]
Operating Leased Assets [Line Items]
Area of leased property (in square feet)	140,000
Operations Support and Training Offices [Member]
Operating Leased Assets [Line Items]
Area of leased property (in square feet)	70,000
Office Space in Chandler [Member]
Operating Leased Assets [Line Items]
Area of leased property (in square feet)	92,000

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions [Abstract]
Expected Volatility (in hundredths)	54.60%	53.80%	54.40%
Expected Dividends (in hundredths)	0.00%	0.00%	0.00%
Expected Term	4 years 8 months 12 days	5 years 1 month 6 days	5 years 1 month 6 days
Risk-Free Rate (in hundredths)	2.40%	1.90%	2.00%
Share-based compensation costs	$8,349,000	$7,116,000	$6,371,000
Shares [Roll Forward]
Outstanding, beginning of period (in shares)	4,325,000
Granted (in shares)	98,000
Exercised (in shares)	-224,000
Forfeited (in shares)	-80,000
Expired (in shares)	-555,000
Outstanding, end of period (in shares)	3,564,000	4,325,000
Exercisable, end of period (in shares)	1,942,000
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$15.09
Granted (in dollars per share)	$16.60
Exercised (in dollars per share)	$12.75
Forfeited (in dollars per share)	$12.87
Expired (in dollars per share)	$29.94
Outstanding, end of period (in dollars per share)	$13.01	$15.09
Exercisable, end of period (in dollars per share)	$14.26
Weighted-Average Remaining Contractual Term (years) [Abstract]
Outstanding at December 31, 2014	6 years 4 months 24 days
Exercisable at December 31, 2014	5 years 6 months
Aggregate Intrinsic Value [Abstract]
Outstanding at December 31, 2014	27,511,000
Exercisable at December 31, 2014	13,940,000
Weighted average grant-date fair value of options per share (in dollars per share)	$9.05	$7.29	$4.01
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation	8,300,000	7,100,000	6,400,000
Total income tax benefit recognized	3,300,000	2,800,000	2,500,000
Total intrinsic value of options exercised during period	1,100,000	3,200,000	1,300,000
Award vesting period	4 years
Total grant date fair value of shares vested	2,500,000	3,100,000	3,600,000
Cash received from option exercised	2,851,000	12,748,000	2,835,000
Tax benefit realized from options exercised	400,000
Expiration period	10 years
Number of shares reserved for future equity grants (in shares)	500,000
Total unrecognized compensation cost related to nonvested share-based compensation arrangements granted	21,400,000
Weighted average period for recognition of unrecognized compensation cost	2 years 2 months 12 days
Share-Based Compensation Included in Cost of Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation	3,800,000	2,900,000	3,000,000
Share-Based Compensation Included in Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation	$4,500,000	$4,200,000	$3,400,000
Restricted Stock and Restricted Stock Units (RSUs) [Member]
Aggregate Intrinsic Value [Abstract]
Weighted average grant-date fair value of options per share (in dollars per share)	$16.72	$13.12	$8.29
Shares [Roll Forward]
Nonvested, beginning of period (in shares)	841,000
Granted (in shares)	475,000
Vested (in shares)	-231,000
Forfeited (in shares)	-38,000
Nonvested, end of period (in shares)	1,047,000	841,000
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share)	$10.44
Granted (in dollars per share)	$16.72
Vested (in dollars per share)	$10.83
Forfeited (in dollars per share)	$11.80
Nonvested, end of period (in dollars per share)	$13.15	$10.44
Performance Shares [Member]
Aggregate Intrinsic Value [Abstract]
Weighted average grant-date fair value of options per share (in dollars per share)	$14.77	$0	$0
Shares [Roll Forward]
Nonvested, beginning of period (in shares)	0
Granted (in shares)	341,000
Vested (in shares)	0
Forfeited (in shares)	0
Nonvested, end of period (in shares)	341,000	0
Weighted-Average Grant Date Fair Value [Roll Forward]
Nonvested, beginning of period (in dollars per share)	$0
Granted (in dollars per share)	$14.77
Vested (in dollars per share)	$0
Forfeited (in dollars per share)	$0
Nonvested, end of period (in dollars per share)	$14.77	$0

Earnings_Loss_Per_Share_Detail

Earnings (Loss) Per Share (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, except Per Share data, unless otherwise specified

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Numerator [Abstract]

Net income (loss)- numerator for basic earnings per share

$2,578

[1],[2]

$1,973

[1]

($517)

[1],[3]

($9,596)

[1],[2],[3]

($5,290)

[1],[3]

$1,799

[1]

($1,101)

[3]

($3,949)

[3]

($5,561)

($8,541)

$8,024

Denominator [Abstract]

Shares used for basic earnings (loss) per share (in shares)

35,302

34,489

33,597

Shares used for diluted earnings (loss) per share (in shares)

35,302

[4]

34,489

[4]

33,836

Earnings (loss) per share [Abstract]

Basic (in dollars per share)

($0.16)

($0.25)

$0.24

Diluted (in dollars per share)

($0.16)

[4]

($0.25)

[4]

$0.24

Non-Qualified Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive (in shares)

1,865

3,234

4,926

Restricted Stock Units [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive (in shares)

453

334

193

Performance Stock Units

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive (in shares)

20

0

0

Warrants Related to Cash Convertible Notes [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive (in shares)

7,707

7,707

0

CareFirst Convertible Note [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive (in shares)

892

892

0

CareFirst Warrants

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive (in shares)

87

0

0

Non-Qualified Stock Options [Member]

Denominator [Abstract]

Effect of dilutive stock options and restricted stock units outstanding (in shares)

0

[4]

0

[4]

37

[4]

Restricted Stock Units [Member]

Denominator [Abstract]

Effect of dilutive stock options and restricted stock units outstanding (in shares)

0

[4]

0

[4]

202

[4]

[1]

Includes charges related to non-cash interest associated with amortization of a debt discount of $1.6 million, $1.7 million, $1.7 million, and $1.7 million for the first, second, third and fourth quarter of 2014, respectively, and $1.5 million and $1.6 million for the third and fourth quarter of 2013, respectively.

[2]

Includes charges of approximately $9.4 million in connection with the Company's settlement of a legal matter for the first quarter of 2014 as well as $8.3 million related to two additional legal settlements for the fourth quarter of 2014.

[3]

The assumed exercise of stock-based compensation awards for this period was not considered in the calculation of diluted earnings (loss) per share because the impact would have been anti-dilutive.

[4]

The assumed exercise of stock-based compensation awards for the years ended December 31, 2014 and December 31, 2013 was not considered because the impact would be anti-dilutive.

Accumulated_OCI_Details

Accumulated OCI (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accumulated Other Comprehensive Income Loss [Line Items]
Accumulated OCI, net of tax Beginning Balance	($407)	($929)
Other comprehensive loss before reclassifications, net of tax	-1,947	-566
Amounts reclassified from accumulated OCI, net of tax	306	1,088
Total other comprehensive income, net of tax	-1,641	522	860
Accumulated OCI, net of tax Ending Balance	-2,048	-407	-929
Reclassification adjustments out of AOCI [Abstract]
Reclassification to interest expense	-17,581	-16,079	-14,149
Net Change in Fair Value of Interest Rate Swaps [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Accumulated OCI, net of tax Beginning Balance	-513	-1,790
Other comprehensive loss before reclassifications, net of tax	-135	189
Amounts reclassified from accumulated OCI, net of tax	306	1,088
Total other comprehensive income, net of tax	171	1,277
Accumulated OCI, net of tax Ending Balance	-342	-513
Net Change in Fair Value of Interest Rate Swaps [Member] | Amounts reclassified from accumulated other comprehensive income to: [Member]
Reclassification adjustments out of AOCI [Abstract]
Reclassification to interest expense	507	1,916
Tax effect of reclassification	-201	-828
Reclassification Adjustment on Derivatives Included in Net Income	306	1,088
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Accumulated OCI, net of tax Beginning Balance	106	861
Other comprehensive loss before reclassifications, net of tax	-1,812	-755
Amounts reclassified from accumulated OCI, net of tax	0	0
Total other comprehensive income, net of tax	-1,812	-755
Accumulated OCI, net of tax Ending Balance	($1,706)	$106

Employee_Benefits_Details

Employee Benefits (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Benefits [Abstract]
Company contributions under the 401(k) Plan	$3.30	$3.10	$2.90

Segment_Disclosures_Details

Segment Disclosures (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
	Segment
Segment Disclosures [Abstract]
Number of reportable segments	1
Percentage of revenues from one customer (in hundredths)	11.60%	10.50%

Quarterly_Financial_Informatio2

Quarterly Financial Information (unaudited) (Details) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information (unaudited) [Abstract]
Revenues	$199,136	[1],[2]	$185,656	[1]	$180,613	[1],[3]	$176,777	[1],[2],[3]	$169,235	[1],[3]	$166,615	[1]	$162,270	[3]	$165,165	[3]	$742,183	$663,285	$677,170
Gross margin	35,058	[1],[2]	27,314	[1]	24,533	[1],[3]	19,257	[1],[2],[3]	18,326	[1],[3]	26,391	[1]	19,916	[3]	15,083	[3]
Income (loss) before income taxes	2,551	[1],[2]	2,998	[1]	-814	[1],[3]	-14,884	[1],[2],[3]	-7,591	[1],[3]	1,108	[1]	-1,650	[3]	-6,044	[3]	-10,148	-14,177	14,746
Net income (loss)	2,578	[1],[2]	1,973	[1]	-517	[1],[3]	-9,596	[1],[2],[3]	-5,290	[1],[3]	1,799	[1]	-1,101	[3]	-3,949	[3]	-5,561	-8,541	8,024
Basic earnings (loss) per share (in dollars per share)	$0.07	[1],[2],[4]	$0.06	[1],[4]	($0.01)	[1],[3],[4]	($0.27)	[1],[2],[3],[4]	($0.15)	[1],[3],[4]	$0.05	[1],[4]	($0.03)	[3],[4]	($0.12)	[3],[4]
Diluted earnings (loss) per share (in dollars per share)	$0.07	[1],[2],[4]	$0.05	[1],[4]	($0.01)	[1],[3],[4]	($0.27)	[1],[2],[3],[4]	($0.15)	[1],[3],[4]	$0.05	[1],[4]	($0.03)	[3],[4]	($0.12)	[3],[4]
Restructuring and related charges																	$0	$0	$1,773
[1]	Includes charges related to non-cash interest associated with amortization of a debt discount of $1.6 million, $1.7 million, $1.7 million, and $1.7 million for the first, second, third and fourth quarter of 2014, respectively, and $1.5 million and $1.6 million for the third and fourth quarter of 2013, respectively.
[2]	Includes charges of approximately $9.4 million in connection with the Company's settlement of a legal matter for the first quarter of 2014 as well as $8.3 million related to two additional legal settlements for the fourth quarter of 2014.
[3]	The assumed exercise of stock-based compensation awards for this period was not considered in the calculation of diluted earnings (loss) per share because the impact would have been anti-dilutive.
[4]	We calculated earnings per share for each of the quarters based on the weighted average number of shares and dilutive securities outstanding for each period. Accordingly, the sum of the quarters may not necessarily be equal to the full year income per share.